

DOCKET NO.: 218975 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ayako TODA, et al.
SERIAL NO.: NEW U.S. PCT APPLICATION
FILED: HERewith
INTERNATIONAL APPLICATION NO.: PCT/JP01/01204
INTERNATIONAL FILING DATE: February 20, 2001
FOR: CYCLIC HEXAPEPTIDE DERIVATIVES

**REQUEST FOR PRIORITY UNDER 35 U.S.C. 119
AND THE INTERNATIONAL CONVENTION**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

| <u>COUNTRY</u> | <u>APPLICATION NO</u> | <u>DAY/MONTH/YEAR</u> |
|----------------|-----------------------|-----------------------|
| Australia | PQ5752 | 21 February 2000 |
| Australia | PQ9552 | 21 August 2000 |
| Australia | PR2344 | 28 December 2000 |

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/JP01/01204. Receipt of the certified copy(s) by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

Respectfully submitted,
OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618
Surinder Sachar
Registration No. 34,423



22850

(703) 413-3000
Fax No. (703) 413-2220
(OSMMN 1/97)



PCT/JP 01/01204

15.03.01

REC'D 30 MAR 2001

WIPO


PCT

JP 01/1204

Patent Office
Canberra

4

I, JONNE YABSLEY, ACTING TEAM LEADER EXAMINATION SUPPORT
& SALES hereby certify that annexed is a true copy of the Provisional
specification in connection with Application No. PQ 5752 for a patent by
FUJISAWA PHARMACEUTICAL CO., LTD filed on 21 February 2000.



WITNESS my hand this
Twentieth day of February 2001

J R Yabsley

JONNE YABSLEY
ACTING TEAM LEADER
EXAMINATION SUPPORT & SALES

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Fujisawa Pharmaceutical Co., Ltd.

A U S T R A L I A
Patents Act 1990

PROVISIONAL SPECIFICATION
for the invention entitled:

"New Compound"

The invention is described in the following statement:

DESCRIPTION

NEW COMPOUND

5 TECHNICAL FIELD

The present invention relates to new polypeptide compounds and salts thereof which are useful as a medicament.

BACKGROUND ART

10 In U.S. Pat. No. 5,376,634, 5,569,646, WO 96/11210 and WO 99/40108, there are disclosed the polypeptide compound and a pharmaceutically acceptable salt thereof, which have antimicrobial activities (especially antifungal activity).


15 DISCLOSURE OF INVENTION

The present invention relates to new polypeptide compound and a salt thereof.

More particularly, it relates to new polypeptide compound and a salt thereof, which have antimicrobial
20 activities [especially, antifungal activities, in which the fungi may include Aspergillus, Cryptococcus, Candida, Mucor, Actinomyces, Histoplasma, Dermatophyte, Malassezia, Fusarium and the like.], inhibitory activity on β -1,3-glucan synthase, and further which are expected to be useful for the
25 prophylactic and/or therapeutic treatment of Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal, to a process for preparation thereof, to a pharmaceutical composition comprising the same, and to a methods for the prophylactic and/or therapeutic
30 treatment of infectious disease including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

The object polypeptide compounds of the present
35 invention are new and can be represented by the following

general formula (I) :



wherein

R¹ is hydrogen or acyl group,

R² and R³ are independently hydrogen, lower alkyl which may have one or more suitable substituent(s) or acyl group,



R⁴ is hydrogen or hydroxy, and



R⁵ is hydrogen, hydroxy or hydroxysulfonyloxy,



R⁶ is hydroxy or acyloxy,



or a salt thereof.

The new polypeptide compound (I) or a salt thereof can be prepared by the process as illustrated in the following reaction schemes.

Process 1


Process 2

Process 3

Process 4

The Starting compound (II) or a salt thereof can be prepared by the process as illustrated in the following reaction scheme.

5 Process A



wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are defined above,

R_a^1 is acyl group,

R_a^2 is hydrogen, lower alkyl which may have one or more suitable substituent(s) or acyl group,
 R_a^3 is lower alkyl which may have one or more suitable substituent(s) or acyl group,
 R_b^3 is amino protective group,
 R_a^5 is hydroxysulfonyloxy, and
 R_b^5 is hydroxy.

Suitable salt of the new polypeptide compound (I) is a pharmaceutically acceptable and conventional non-toxic salt, and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, diisopropylethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, , N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride hydrobromide, sulfate, phosphate, etc.); an organic carboxylic sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.).

Suitable examples and illustration of the various definitions in the above and subsequent descriptions of the present specification, which the present invention intends to include within the scope thereof, are explained in detail as follows :

The term "lower" is used to intend a group having 1 to 6

carbon atom(s), unless otherwise provided.

Suitable example of "one or more" may be the number of 1 to 6, in which the preferred one may be the number of 1 to 3.

5 Suitable example of "lower alkoxy" may include straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, tert-pentyloxy, neo-pentyloxy, hexyloxy, isohexyloxy and the like.

10 Suitable example of "higher alkoxy" may include straight or branched one such as heptyloxy, octyloxy, 3,5-dimethyloctyloxy, 3,7-dimethyloctyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tridecyloxy, tetradecyloxy, hexadecyloxy, heptadecyloxy, octadecyloxy, nonadecyloxy, icosyloxy, and the like.

15 Suitable example of "lower alkyl" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, neo-pentyl, hexyl, isohexyl and the like.

20 Suitable example of "aryl" and "ar" moiety may include phenyl which may have lower alkyl (e.g., phenyl, mesityl, xylyl, tolyl, etc.), naphthyl, anthryl, indanyl, fluorenyl and the like.

 Suitable example of "aroyl" may include benzoyl, toluoyl, naphthoyl, anthrylcarbonyl, and the like.

25 Suitable example of "heterocyclic group" may include unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, 30 pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;

35 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl,

piperidyl, piperazinyl, azetidiny, etc.;

unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indoliziny, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, morpholino, etc.;

unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example thiazolidinyl, thiomorpholinyl, thiomorpholino, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s), for example, thienyl, dihydrodithiiny, dihydrodithionyl, etc.;

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, imidazothiadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-

membered) heteromonocyclic group containing an oxygen atom, for example, furyl etc.;

5 saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s), for example, tetrahydrofuran, tetrahydropyran, dioxacyclopentane, dioxacyclohexane, etc.;

10 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s), for example benzothienyl, benzodithiinyl, etc.;

15 unsaturated condensed heterocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, benzoxathiinyl, etc.; and the like and this "heterocyclic group" may have one or more lower alkyl.

20 Suitable example of "cyclo(lower)alkyl" may include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

Suitable example of "cyclo(lower)alkyloxy" may include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

25 Suitable example of "acyl group" may include aliphatic acyl, aromatic acyl, arylaliphatic acyl and heterocyclic-aliphatic acyl derived from carboxylic acid, carbonic acid, carbamic acid, sulfonic acid, and the like.

30 Suitable example of said "acyl group" may be illustrated as follows.

35 Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl,

- tridecanoyl, tetradecanoyl, pentadecanoyl, palmitoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.);
- lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.);
- lower alkenyloxycarbonyl (e.g., vinyloxycarbonyl, propenyloxycarbonyl, allyloxycarbonyl, butenyloxycarbonyl, butadienyloxycarbonyl, pentenyloxycarbonyl, hexenyloxycarbonyl, etc.);
- lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.);
- lower or higher alkoxysulfonyl (e.g., methoxysulfonyl, ethoxysulfonyl, etc.); or the like;
- Aromatic acyl such as
- aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.);
- ar(lower)alkanoyl [e.g., phenyl(C₁-C₆)alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl(C₁-C₆)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.];
- ar(lower)alkenoyl [e.g., phenyl(C₃-C₆)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentanoyl, phenylhexenoyl, etc.), naphthyl(C₃-C₆)alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, etc.), etc.];
- ar(lower)alkoxycarbonyl [e.g., phenyl(C₁-C₆)alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), fluorenyl(C₁-C₆)alkoxycarbonyl (e.g., fluorenylmethyloxycarbonyl, etc.), etc.];
- aryloxycarbonyl (e.g., phenoxycarbonyl, naphthyloxycarbonyl, etc.);
- aryloxy(lower)alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.);
- arylcarbamoyl (e.g., phenylcarbamoyl, etc.);
- arylthiocarbamoyl (e.g., phenylthiocarbamoyl, etc.);
- arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl,

etc.);

arylsulfonyl which may have 1 to 4 lower alkyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc.); or the like;

Heterocyclic acyl such as

5 heterocycliccarbonyl;

heterocyclic(lower)alkanoyl (e.g., heterocyclicacetyl, heterocyclicpropanoyl, heterocyclicbutanoyl, heterocyclicpentanoyl, heterocyclichexanoyl, etc.);

10 heterocyclic(lower)alkenoyl (e.g., heterocyclicpropenoyl, heterocyclicbutenoyl, heterocyclicpentenoyl, heterocyclichexenoyl, etc.);

heterocyclicglyoxyloyl; or the like;

in which suitable "heterocyclic" moiety in the terms

"heterocycliccarbonyl", "heterocyclic(lower)alkanoyl",
15 "heterocyclic(lower)alkenoyl" and "heterocyclicglyoxyloyl"
can be referred to aforementioned "heterocyclic" moiety, and
these "acyl group" may have one or more suitable
substituent(s) selected from the group consisting of lower
alkyl, oxo, and amino.

20

Suitable example of "acyl group" of R^1 can be referred
to aforementioned "acyl group", in which the preferred one
may be higher alkanoyl, lower alkoxy carbonyl, aroyl which may
have one or more suitable substituent(s) and the like.

25

Suitable example of "suitable substituent(s)" in the
term of "aroyl substituted with one or more suitable
substituent(s)" may be heterocyclic group substituted with
aryl having lower alkoxy, heterocyclic group substituted with
30 aryl having lower alkoxy(lower)alkoxy, heterocyclic group
substituted with aryl having lower alkoxy(higher)alkoxy,
heterocyclic group substituted with aryl having
cyclo(lower)alkyloxy, heterocyclic group substituted with
aryl having heterocyclic group, heterocyclic group
35 substituted with cyclo(lower)alkyl having cyclo(lower)alkyl,

heterocyclic group substituted with aryl having aryl
 substituted with lower alkoxy(lower)alkoxy, heterocyclic
 group substituted with aryl having heterocyclic group
 substituted with cyclo(lower)alkyl having lower alkyl and
 5 heterocyclic group substituted with aryl having heterocyclic
 group substituted with lower alkoxy(lower)alkoxy, in which
 the preferred one may be unsaturated condensed heterocyclic
 group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen
 atom(s) substituted with phenyl having (C₄-C₆)alkoxy,
 10 unsaturated 3 to 8-membered heteromonocyclic group containing
 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) substituted
 with phenyl having (C₁-C₄)alkoxy(C₄-C₆)alkoxy, unsaturated 3
 to 8-membered heteromonocyclic group containing 1 or 2 sulfur
 atom(s) and 1 to 3 nitrogen atom(s) substituted with phenyl
 15 having (C₁-C₄)alkoxy(C₇-C₁₄)alkoxy, saturated 3 to 8-membered
 heteromonocyclic group containing 1 to 4 nitrogen atom(s)
 substituted with phenyl having (C₁-C₄)alkoxy(C₇-C₁₄)-
 alkoxy, unsaturated condensed heterocyclic group containing 1
 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) substituted
 20 with phenyl having cyclo(C₄-C₆)alkoxy, unsaturated
 condensed heterocyclic group containing 1 or 2 sulfur atom(s)
 and 1 to 3 nitrogen atom(s) substituted with phenyl having
 saturated 3 to 8-membered heteromonocyclic group containing 1
 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), saturated 3
 25 to 8-membered heteromonocyclic group containing 1 to 4
 nitrogen atom(s) substituted with cyclo(C₄-C₆)alkyl having
 cyclo(C₄-C₆)alkyl, unsaturated 3 to 8-membered
 heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1
 to 3 nitrogen atom(s) substituted with phenyl having phenyl
 30 substituted with (C₁-C₄)alkoxy(C₁-C₄)alkoxy, unsaturated 3 to
 8-membered heteromonocyclic group containing 1 or 2 sulfur
 atom(s) and 1 to 3 nitrogen atom(s) substituted with phenyl
 having saturated 3 to 8-membered heteromonocyclic group
 containing 1 to 4 nitrogen atom(s) substituted with cyclo(C₄-
 35 C₆)alkyl having (C₁-C₄)alkyl, unsaturated condensed

heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) substituted with phenyl having saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s) having cyclo(C₄-C₆)alkyl and unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) substituted with phenyl having saturated 3 to 8-membered heteromonocyclic group 1 to 4 nitrogen atom(s) substituted with (C₁-C₄)alkoxy(C₄-C₆)alkoxy, and the most preferred one may be imidazothiadiazolyl substituted with phenyl having pentyloxy, thiadiazolyl substituted with phenyl having methoxyhexyloxy, thiadiazolyl substituted with phenyl having methoxyoctyloxy, thiadiazolyl substituted with phenyl having methoxyheptyloxy, imidazothiadiazolyl substituted with phenyl having cyclohexyloxy, imidazothiadiazolyl substituted with phenyl having dimethylmorpholino, piperazinyll substituted with phenyl having methoxyheptyloxy, piperazinyll substituted with phenyl having methoxyoctyloxy, piperazinyll substituted with cyclohexyl having cyclohexyl, thiadiazolyl substituted with phenyl having phenyl substituted with methoxyethoxy, thiadiazolyl substituted with phenyl having phenyl substituted with methoxybutoxy, thiadiazolyl substituted with phenyl having phenyl substituted with ethoxypropoxy, imidazothiadiazolyl substituted with phenyl having piperazinyll substituted with cyclohexyl, imidazothiadiazolyl substituted with phenyl having piperazinyll substituted with cyclohexyl, thiadiazolyl substituted with phenyl having piperazinyll substituted with methylcyclohexyl and imidazothiadiazolyl substituted with phenyl having piperidyl substituted with methoxypentyloxy.

The more suitable example of "acyl group" may be palmitoyl, tert-butoxycarbonyl, benzoyl which has imidazolthiadiazolyl substituted with phenyl having pentyloxy, benzoyl which has thiadiazolyl substituted with phenyl having methoxyhexyloxy, benzoyl which has thiadiazolyl substituted with phenyl having methoxyoctyloxy, benzoyl which

has thiadiazolyl substituted with phenyl having methoxyheptyloxy, benzoyl which has imidazothiadiazolyl substituted with phenyl having cyclohexyloxy, benzoyl which has imidazothiadiazolyl substituted with phenyl having dimethylmorpholino, benzoyl which has piperazinyl substituted with phenyl having methoxyheptyloxy, benzoyl which has piperazinyl substituted with phenyl having methoxyoctyloxy, benzoyl which has piperazinyl substituted with cyclohexyl having cyclohexyl, benzoyl which has thiadiazolyl substituted with phenyl having phenyl substituted with methoxyethoxy, benzoyl which has thiadiazolyl substituted with phenyl having phenyl substituted with methoxybutoxy, benzoyl which has thiadiazolyl substituted with phenyl having phenyl substituted with ethoxypropoxy, benzoyl which has imidazothiadiazolyl substituted with phenyl having piperazinyl substituted with cyclohexyl, benzoyl which has imidazothiadiazolyl substituted with phenyl having piperazinyl substituted with cyclohexyl, benzoyl which has thiadiazolyl substituted with phenyl having piperazinyl substituted with methylcyclohexyl and benzoyl which has imidazothiadiazolyl substituted with phenyl having piperidyl substituted with methoxypentyloxy.

Suitable example of "lower alkyl" in the term of "lower alkyl which may have one or more suitable substituent(s)" can be referred to aforementioned "lower alkyl", in which the preferred one may be methyl, ethyl, propyl, isopropyl, buthyl, pentyl and hexyl.

Suitable example of "suitable substituent(s)" in the term of "lower alkyl which may have one or more suitable substituent(s)" may be imino, amino, carbamoyl, lower alkoxy, hydroxy, and the like.

Suitable example of "lower alkyl which may have one or more suitable substituent(s)" may be iminomethyl, 1-iminoethyl, amidino, 1-imino-2-carbamoylethyl, 1-imino-3-

methoxypropyl, carboxymethyl, 3-aminopropyl, 1-methylpyrazol-4-ylmethyl, dihydroxyisopropyl, 2,3-dihydroxypropyl, 2,3,4-trihydroxybutyl, 2,3,4,5-tetrahydroxypentyl, 2,3,4,5,6-pentahydroxyhexyl.

5

Suitable example of "acyl group" of R^2 and R^3 can be referred to aforementioned "acyl group", in which the preferred one may be "amino protective group" mentioned below, and the most preferred one may be acetyl, 2-acetyloxypropionyl, methylsulfonyl, 2,5-diaminopentanoyl, benzyloxycarbonyl, fluorenylmethoxycarbonyl, allyloxycarbonyl and tert-butoxycarbonyl.

15

Suitable example of "amino protective group" may be a conventional protective group such as ar(lower)alkoxycarbonyl, lower alkenyloxycarbonyl and lower alkoxy carbonyl, in which the preferred one may be phenyl(C_1-C_4)alkoxycarbonyl, fluorenyl(C_1-C_4)alkoxycarbonyl, (C_2-C_4)alkenyloxycarbonyl and (C_1-C_4)alkoxycarbonyl, and the most preferred one may be benzyloxycarbonyl, fluorenylmethoxycarbonyl, allyloxycarbonyl and tert-butoxycarbonyl.

20

Suitable example of "acyl" moiety of "acyloxy" can be referred to aforementioned "acyl", in which the preferred one may be lower alkenyloxycarbonyl, and the most preferred one may be allyloxycarbonyl.

25

Suitable example of "acyoxy" may be lower alkenyloxycarbonyloxy, and the most preferred one may be allyloxycarbonyloxy.

30

Process 1

The object compound (Ia) or a salt thereof can be prepared by reducing a compound (II) or a salt thereof.

35

Suitable salts of the compounds (Ia) and (II) may be the

same as those exemplified for the compound (I).

The reaction can be carried out in a conventional manner namely, chemical reduction or catalytic reduction.

Suitable reducing agents to be used in chemical
5 reduction are a combination of metal [e.g. tin, zinc, iron,
etc.] or metallic compound [e.g. chromium chloride, chromium
acetate, etc.] and an organic or inorganic acid [e.g. formic
acid, acetic acid, propionic acid, trifluoroacetic acid,
p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid,
10 hydride transfer reagent such as aluminum hydride compound
(e.g. lithium aluminum hydride, lithium hydridotri-t-
butoxyaluminate, etc.), borohydride compound (e.g. sodium
borohydride, sodium cyanoborohydride, etc.) or the like
etc.].

15 Suitable catalysts to be used in catalytic reduction are
conventional ones such as platinum catalyst [e.g. platinum
plate, spongy platinum, platinum black, colloidal platinum,
platinum oxide, platinum wire, etc.], palladium catalyst
[e.g., spongy palladium, palladium black, palladium oxide,
20 palladium on carbon, colloidal palladium, palladium on barium
sulfate, palladium on barium carbonate, etc.], nickel
catalyst [e.g. reduced nickel, nickel oxide, Raney nickel,
etc.], cobalt catalyst [e.g. reduced cobalt, Raney cobalt,
etc.], iron catalyst [e.g. reduced iron, Raney iron, etc.],
25 copper catalyst [e.g. reduced copper, Raney copper, Ullman
copper, etc.] or the like.

The reaction of this process is usually carried out in a
solvent such as water, alcohol [e.g. methanol, ethanol,
propanol, etc.], acetic acid, diethyl ether, dioxane,
30 tetrahydrofuran, methylene chloride, etc. or a mixture
thereof.

The reaction is preferably carried out under somewhat
milder conditions such as under cooling to warming.

It is included within the scope of the present invention
35 that "hydroxy" in R⁴ may be reduced to "hydrogen" during the

reaction.

Process 2

5 The object compound (Ib) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to protective reaction of amino.

This protective reaction may include acylation or alkylation reaction of amino, and can be carried out according to a conventional manner such as the one described
10 in Examples or the similar manners thereto.

Process 3

The object compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or its reactive
15 derivative at the sulfonic acid group or a salt thereof to hydrolysis reaction of the sulfonic acid group.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base may include an inorganic base and an
20 organic base such as an alkali metal [e.g., sodium potassium, etc.], an alkaline earth metal [e.g., magnesium, calcium, etc.], the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, or the
25 like.

Suitable acid may include an organic acid [e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], and an inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen
30 chloride, hydrogen bromide, etc.].

The elimination using Lewis acid such as trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid, etc.], or the like preferably carried out in the presence of cation trapping agent [e.g., anisole, phenol, etc.].

35 The reaction is usually carried out in a conventional

solvent such as water, alcohol [e.g. methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other
5 organic solvent which do not adversely affect the reaction, or the mixture thereof.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

10 Process 4

The object compound (Ia) or a salt thereof can be prepared by subjecting a compound (Ie) or a salt thereof to elimination reaction of amino protective group.

This reaction is carried out in accordance with a
15 conventional method such as hydrolysis, reduction or the like.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid. Suitable base may include an inorganic base and an organic base such as an
20 alkali metal [e.g. sodium, potassium, etc.], an alkaline earth metal [e.g. magnesium, calcium, etc.], the hydroxide or carbonate or bicarbonate thereof, trialkylamine [e.g. trimethylamine, triethylamine, etc.], picoline, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.
25

Suitable acid may include an organic acid [e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen
30 chloride, hydrogen bromide, etc.]. The elimination using Lewis acid such as trihaloacetic acid [e.g. trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g. anisole, phenol, etc.].

35 The reaction is usually carried out in a solvent such as

water, an alcohol [e.g. methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

The reduction method applicable for the elimination reaction may include chemical reduction and catalytic reduction.

Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g. tin, zinc, iron, etc.] or metallic compound [e.g. chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.].

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts [e.g. platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.], palladium catalysts [e.g. spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium, sulfate, palladium on barium carbonate, etc.], nickel catalysts [e.g. reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalysts [e.g. reduced cobalt, Raney cobalt, etc.], iron catalysts [e.g. reduced iron, Raney iron, etc.], copper catalysts [e.g. reduced copper, Raney copper, Ullman copper, etc.] and the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, N,N-dimethylformamide, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the

above-mentioned solvent, and other conventional solvent such as diethyl ether, dioxane, tetrahydrofuran, etc., or a mixture thereof.

5 The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.

Process A

10 The object polypeptide compound (II) or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the amino group or a salt thereof with the compound (III) or its reactive derivative at the carboxy group or a salt thereof.

15 Suitable reactive derivative at the carboxy group of the compound (III) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.

Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid [e.g., dialkylphosphoric acid, 20 phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.], dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g., methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g., acetic acid, 25 propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid trichloroacetic acid, etc.]; or aromatic carboxylic acid [e.g., benzoic acid, etc.]; a symmetrical acid, anhydride; an activated amide with imidazole, 4-substituted imidazole, 30 dimethylpyrazole, triazole, tetrazole or 1-hydroxy-1H-benzotriazole; or an activated ester [e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl $[(CH_3)_2N^+=CH-]$ ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, 35 pentachloropentyl ester, mesylphenyl ester, phenylazophenyl

ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.], or an ester with a N-hydroxy compound [e.g.

5 N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxyphthalimide, 1-hydroxy-1H-benzotriazole, etc.], and the like. These reactive derivatives can optionally be selected from them according to the mind of the compound (III) to be used.

10 Suitable salts of the compound (III) and its reactive derivative can be referred to the ones as exemplified for the object polypeptide compound (I).

The reaction is usually carried out in a conventional solvent such as water, alcohol [e.g., methanol, ethanol, 15 etc.], acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction. These conventional solvent may also be used in a mixture with 20 water.

In this reaction, when the compound (III) is used in a free acid form or its salt form, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; 25 N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonylbis-(2-methylimidazole); 30 pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine, ethoxyacetylene; 1-alkoxy-2-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); 35 phosphorus trichloride; thionyl chloride; oxalyl chloride;

lower alkyl haloformate [e.g., ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine;
2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-
(m-sulfophenyl)isoxazolium hydroxide intramolecular salt;
1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole;
so-called Vilsmeier reagent prepared by the reaction of
N,N-dimethylformamide with thionyl chloride, phosgene,
trichloromethyl chloroformate, phosphorous oxychloride,
methanesulfonyl chloride, etc.; or the like.

The reaction may also be carried out in the presence of
an inorganic or organic base such as an alkali metal
carbonate, alkali metal bicarbonate, tri(lower)alkylamine
(eg., triethylamine, diisopropylethylamine, etc.), pyridine,
di(lower)alkylaminopyridine (e.g.,
4-dimethylaminopyridine, etc.), N-(lower)alkylmorpholine,
N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the
reaction is usually carried out under cooling to warming.

The compounds obtained by the above Processes 1 to 4 and
Process A can be isolated and purified by a conventional
method such as pulverization, recrystallization, column-
chromatography, high-performance liquid chromatography
(HPLC), reprecipitation, desalting resin column
chromatography, or the like.

The compounds obtained by the above Processes 1 to 4 and
Process A may be obtained as its solvate, such as hydrate,
and its solvate, such as hydrate is included within the scope
of present invention.

It is to be noted that each of the object compound (I)
may include one or more stereoisomer such as optical
isomer(s) and geometrical isomer(s) due to asymmetric carbon
atom(s) and double bond(s) and all such isomers and the
mixture thereof are included within the scope of the present
invention.

The object compound (I) or a salt thereof includes solvated compound [e.g., enclosure compound (e.g., hydrate, etc.)].

5 The object compound (I) or a salt thereof includes both its crystal form and non-crystal form.

It should be understood that the compounds in the present invention may include the prodrug form.

The patent applications and publications cited herein are incorporated by reference.

10

Biological property of the polypeptide
compound (I) of the present invention

In order to show the usefulness of the polypeptide compound (I) of the present invention, the biological data of
15 the representative compound is explained in the following.

Test (Antimicrobial activity) :

In vitro antimicrobial activity of the object compound of Example 5, 22, and 27 disclosed later was determined by
20 MIC_S in mouse serum method as described below.

Test Method :

The MIC_S in mouse serum were determined by the microdilution method using ICR mouse serum buffered with 20
25 mM HEPES buffer (pH 7.3) as a test medium. Inoculum suspension of 10⁶ cells/ml were prepared by a hemocytometric procedure and diluted to obtain an inoculum size of approximately 1.0 x 10³ cells/ml. Microplates were incubated at 37°C for 24 hours in 5% CO₂. The MIC_S were defined as the
30 lowest concentrations at which no visible growth was observed.

35

Test Result : MIC ($\mu\text{g/ml}$)

| Test compound \ Test organism | Candida albicans FP-633 |
|--|-------------------------|
| The object compound of <u>Example 5</u> | < 0.3 |
| The object compound of <u>Example 22</u> | < 0.3 |
| The object compound of <u>Example 27</u> | < 0.3 |

From the test result, it is realized that the object polypeptide compound (I) of the present invention has an antimicrobial activity (especially, antifungal activity).

The pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the object polypeptide compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient in admixture with an organic or inorganic carrier or excipient which is suitable for rectal; pulmonary (nasal or buccal inhalation); ocular; external (topical); oral administration; parenteral (including subcutaneous, intravenous and intramuscular) administrations; insufflation (including aerosols from metered dose inhalator); nebulizer; or dry powder inhalator.

The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers in a solid form such as granules, tablets, dragees, pellets, troches, capsules, or suppositories; creams; ointments; aerosols; powders for insufflation; in a liquid form such as solutions, emulsions, or suspensions for injection; ingestion; eye drops; and any other form suitable for use. And, if necessary, there may be included in the

above preparation auxiliary substance such as stabilizing, thickening, wetting, emulsifying and coloring agents; perfumes or buffer; or any other commonly may be used as additives.

5 The object polypeptide compound (I) or a pharmaceutically acceptable salt thereof is/are included in the pharmaceutical composition in an amount sufficient to produce the desired antimicrobial effect upon the process or condition of diseases.

10 For applying the composition to human, it is preferable to apply it by intravenous, intramuscular, pulmonary, oral administration, eye drop administration or insufflation. While the dosage of therapeutically effective amount of the object polypeptide compound (I) varies from and also depends
15 upon the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01-20 mg of the object polypeptide compound (I) per kg weight of human being in the case of intramuscular administration, a daily dose of 0.1-20 mg of the object
20 polypeptide compound (I) per kg weight of human being, in case of oral administration, a daily dose of 0.5-50 mg of the object polypeptide compound (I) per kg weight of human being is generally given for treating or preventing infectious diseases.

25 Especially in case of the treatment of prevention of Pneumocystis carinii infection, the followings are to be noted.

 For administration by inhalation, the compounds of the present invention are conveniently delivered in the form of an
30 aerosol spray presentation from pressurized as powders which may be formulated and the powder compositions may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery system for inhalation is a metered dose inhalation aerosol, which may be formulated as a suspension
35 or solution of compound in suitable propellants such as

fluorocarbons or hydrocarbons.

Because of desirability to directly treat lung and bronchi, aerosol administration is a preferred method of administration. Insufflation is also a desirable method,
5 especially where infection may have spread to ears and other body cavities.

Alternatively, parenteral administration may be employed using drip intravenous administration.

10 The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.



The Starting Compounds used and the Object Compounds
15 obtained in the following Preparations 1 to 23 are given in the table as below, in which the formulas of the starting compounds are in the upper column and the formulas of the object compounds are in the lower column, respectively.





20





25





30





35





| Preparation No. | Formula |
|--------------------|---|
| 1 |  |
| |  |














| Preparation No. | Formula |
|--------------------|--|
| 2 |  |
| |  |
| 3 |  |
| |  |


| Preparation No. | Formula |
|-----------------|--|
| 4 |  |
| |  |
| 5 |  |
| |  |

| Preparation No. | Formula |
|-----------------|--|
| 6 |  |
| |  |
| 7 |  |
| |  |



| Preparation No. | Formula |
|--------------------|--|
| 8 |  <p>Chemical structure of a complex molecule, likely a derivative of a natural product. It features a central core with multiple hydroxyl groups, a nitrile group, a methyl group, and a sodium sulfonate group.</p> |
| |  <p>Chemical structure of a complex molecule, likely a derivative of a natural product. It features a central core with multiple hydroxyl groups, a nitrile group, a methyl group, and a sodium sulfonate group.</p> |
| 9 |  <p>Chemical structure of a complex molecule, likely a derivative of a natural product. It features a central core with multiple hydroxyl groups, a nitrile group, a methyl group, and a sodium sulfonate group.</p> |
| |  <p>Chemical structure of a complex molecule, likely a derivative of a natural product. It features a central core with multiple hydroxyl groups, a nitrile group, a methyl group, and a sodium sulfonate group.</p> |



| Preparation No. | Formula |
|----------------------|--|
| 10 |  |
| |  |
| <div>11 21</div> |  |
| |  |

| Preparation No. | R | X |
|-----------------|--|---|
| 5 11 |  | Na |
| 12 |  | Na |
| 10 13 |  | Na |
| 14 |  | Na |
| 15 15 |  |  |
| 16 |  |  |
| 20 17 |  | Na |
| 18 |  |  |
| 25 19 |  | Na |
| 20 |  | Na |

| Preparation No. | R | X |
|-----------------|--|----|
| 21 |  | Na |

5

| Preparation No. | Formula |
|-----------------|--|
| 22 |  |
| |  |

| Preparation No. | Formula |
|-----------------|---|
| 23 |  |
| |  |

Preparation 1

A solution of Starting compound (20 g) in 1,4-dioxane (100 ml) was treated with a solution of 1N-sodium hydroxide (44.2 ml), diluted to 100 ml with water, and to the stirred mixture was added a solution of di-tert-butylidicarbonate (9.2 g) in 1,4-dioxane (50 ml) and then stirred for 2 hours at room temperature. 500 ml of pH 6.86 phosphate buffer and 100 ml ethyl acetate were added and the mixture was stirred and the organic layer discarded. The aqueous layer was adjusted to pH 7.0 with 1N-hydrochloric acid then evaporated to remove organic solvent, filtered, and purified by ODS column chromatography eluting with aqueous methanol (5-15%). Object compound containing fractions were pooled, evaporated, and lyophilized to give Object compound (19.61 g) as an amorphous

white powder.

NMR (DMSO- d_6 , δ) : 0.95 (3H, d, $J=6.8\text{Hz}$), 1.07 (3H, d, $J=5.5\text{Hz}$), 1.34 (9H, s), 1.40-2.50 (9H, m), 2.80-3.0 (1H, m), 3.4-4.5 (15H, m), 4.70-5.40 (8H, m), 6.60-7.05 (6H, m), 7.25-8.00 (5H, m), 8.71 (1H, s)
 MASS (m/z) : 1003.3 (M^+-H)

Preparation 2

A mixture of Starting compound (500 mg),
 10 N,N-dimethylformamide (5 ml) and synthetic A-4 zeolite (500 mg, Wako Chemical) was treated with diisopropyl ethylamine (66 mg), followed by methanesulfonyl chloride (58.5 mg) dropwise. After 1 hour at room temperature, further diisopropyl ethylamine (66 mg) and methanesulfonyl chloride
 15 (58.5 mg) were added. After 1.5 hours, additional diisopropylamine (66 mg) and methanesulfonyl chloride (58.5 mg) were added. After 1.5 hours, the mixture was filtered and the filtrate was poured into ethyl acetate. The precipitate was collected, washed with ethyl acetate and
 20 dried. The powder was dissolved in saturated sodium hydrogen carbonate solution then purified by ODS column chromatography (Daisogel SP-120 ODS Daiso) eluting with aqueous methanol (5-12.5%). Object compound-containing fractions were pooled, evaporated to remove methanol, and lyophilized to give Object
 25 compound (210 mg) as an amorphous white powder.

IR (KBr) : 2258.2, 1664.3, 1629.6, 1529.3, 1517.7, 1446.4, 1268.9 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.94 (3H, d, $J=6.7\text{Hz}$), 1.07 (3H, d, $J=5\text{Hz}$), 1.40-3.00 (9H, m), 3.10-4.50 (15H, m),
 30 4.50-5.30 (10H, m), 5.66-5.69 (1H, m), 6.73 (1H, d, $J=8.2\text{Hz}$), 6.82 (1H, d, $J=8\text{Hz}$), 7.05 (1H, d, $J=1.7\text{Hz}$), 7.33 (5H, s), 7.20-7.50 (3H, m), 7.6-7.7 (1H, m), 8.27 (1H, d, $J=8.3\text{Hz}$), 8.84 (1H, s)

MASS (m/z) : 1081.3 ($M+\text{Na}^+$)

35 Elemental Analysis Calcd. for $\text{C}_{43}\text{H}_{55}\text{N}_8\text{O}_{20}\text{SNa}\cdot 6\text{H}_2\text{O}$:
 C 44.25, H 5.79, N 9.60

Found : C 44.30, H 5.79, N 9.48

The following compounds [Preparations 3 to 5] were
 obtained according to a similar manner to that of Preparation
 5 2.

Preparation 3

IR (KBr) : 2256.3, 1631.5, 1538.9, 1513.8, 1442.5,
 1257.4 cm^{-1}

10 NMR (DMSO- d_6 , δ) : 0.97 (3H, d, $J=6.7\text{Hz}$), 1.12 (3H, d,
 $J=5.5\text{Hz}$), 1.20-1.60 (8H, m), 1.65-3.05 (13H, m),
 3.21 (3H, s), 3.30 (2H, t, $J=6.4\text{Hz}$), 3.45-4.57
 (16H, m), 4.70-5.30 (7H, m), 5.87 (1H, d, $J=6.1\text{Hz}$),
 6.72 (1H, d, $J=8.2\text{Hz}$), 6.76-6.81 (1H, m), 6.98 (1H,
 15 d, $J=1.3\text{Hz}$), 7.13 (2H, d, $J=8.8\text{Hz}$), 7.40-7.53 (2H,
 m), 7.79 (1H, br s), 7.98 (2H, d, $J=8.7\text{Hz}$), 8.10
 (4H, s), 8.34 (1H, d, $J=7.9\text{Hz}$), 8.72 (1H, d,
 $J=5.7\text{Hz}$), 8.73 (1H, s)

MASS (m/z) : 1293.4 ($\text{M}-\text{Na}^+$)

20 Elemental Analysis Calcd. for $\text{C}_{58}\text{H}_{73}\text{N}_{10}\text{O}_{20}\text{SNa}\cdot 6\text{H}_2\text{O}$:
 C 48.87, H 6.01, N 9.83
 Found : C 48.69, H 6.09, N 9.70

Preparation 4

25 IR (KBr) : 2256.3, 1666.2, 1631.5, 1535.1, 1515.8,
 1448.3, 1442.5, 1272.8, 1251.6, 1166.7, 1083.8,
 1047.2 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.95 (3H, d, $J=6.7\text{Hz}$), 1.09 (3H, d,
 $J=5.1\text{Hz}$), 1.35 (9H, s), 1.50-3.00 (9H, m), 3.10-
 30 4.50 (17H, m), 4.65-5.00 (5H, m), 5.15-5.17 (2H,
 m), 5.70-5.90 (1H, m), 6.68-6.78 (2H, m), 6.86-6.96
 (2H, m), 7.32 (1H, d, $J=8\text{Hz}$), 7.40-7.50 (1H, m),
 7.70-7.80 (1H, m), 8.30-8.40 (1H, m), 8.72 (1H, s)

MASS (m/z) : 985.3 ($\text{M}-\text{Na}^+$)

35 Elemental Analysis Calcd. for $\text{C}_{40}\text{H}_{58}\text{N}_8\text{O}_{19}\text{SNa}\cdot 9\text{H}_2\text{O}$:
 C 41.02, H 6.45, N 9.57

Found : C 41.35, H 6.42, N 9.61

Preparation 5

IR (KBr) : 2256.3, 1668.1, 1648.8, 1631.5, 1538.9,
5 1513.8, 1454.1, 1267.0 cm^{-1}
NMR (DMSO- d_6 , δ) : 0.95 (3H, d, $J=6.8\text{Hz}$), 1.07 (3H, d,
 $J=5.2\text{Hz}$), 1.5-2.9 (10H, m), 3.2-4.5 (15H, m), 4.7-
5.2 (9H, m), 5.7-5.8 (1H, m), 6.60-6.78 (2H, m),
6.96 (1H, br s), 7.33 (5H, s), 7.2-7.5 (3H, m),
10 7.7-7.8 (1H, m), 8.3 (1H, d, $J=7.5\text{Hz}$), 8.73 (1H, br
s)

MASS (m/z) : 1065.2 ($M+\text{Na}^+$)

Elemental Analysis Calcd. for $\text{C}_{43}\text{H}_{55}\text{N}_8\text{O}_{19}\text{SNa}\cdot 7\text{H}_2\text{O}$:

C 44.18, H 5.95, N 9.58

15 Found : C 44.21, H 5.82, N 9.54

Preparation 6

A solution of Starting compound (2.0 g) in methanol (100
ml) - water (20 ml) was treated with cobalt(II) chloride
20 hexahydrate (1.89 g) and then stirred to give a pink
solution. Sodium borohydride (1.5 g) was then added
portionwise and then stirred for 1 hour at room temperature.
The reaction mixture was filtered through a bed of celite,
washing with methanol (100 ml) - water (30 ml) solution. The
25 ice-cooled filtrate was then treated dropwise with a solution
of benzyloxy carbonyl chloride (Z-chloride) (0.34 ml) in
tetrahydrofuran (5 ml) and stirred for 1 hour at the same
temperature. Ethyl acetate (50 ml) was added followed by
water (200 ml) and after stirring ~ 5 minutes, the separated
30 organic layer was discarded. The aqueous layer was adjusted
to pH 8.8 and evaporated to remove organic solvent and then
purified by ODS column chromatography, eluting with aqueous
acetonitrile (10-30%). Object compound containing fractions
were pooled, evaporated, and lyophilized to give Object
35 compound (1.61 g) as an amorphous white powder.

IR (KBr) : 1666.2, 1631.5, 1517.7, 1444.4, 1267.0 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.94 (3H, d, $J=6.7\text{Hz}$), 1.00-1.15
 (3H, m), 1.33 (9H, s), 1.35-2.10 (6H, m), 2.10-2.50
 (4H, m), 2.80-3.30 (4H, m), 3.60-4.55 (12H, m),
 4.60-4.90 (2H, m), 4.99 (2H, s), 4.50-5.30 (4H, m),
 5 6.60-7.10 (4H, m), 7.33 (5H, s), 7.35-7.90 (3H, m),
 8.72 (1H, br s)

MASS (m/z) : 1123.3 ($M-\text{Na}^+$)

Elemental Analysis Calcd. for $\text{C}_{48}\text{H}_{67}\text{N}_8\text{O}_{21}\text{SNa}\cdot 6\text{H}_2\text{O}$:

C 45.93, H 6.34, N 8.93

10 Found : C 45.68, H 6.33, N 8.82

Preparation 7

A solution of Starting compound (2.0 g) in methanol (30 ml) was treated with wet 10% palladium on carbon (1.5 g) and
 15 exposed to one atmosphere of hydrogen gas via balloon. After
 5.5 hours, water (4 ml) was added and hydrogenation continued
 for a further 30 minutes. Methanol (100 ml) was added and
 the catalyst removed by filtration. The solution was
 concentrated in vacuo to remove methanol and the aqueous
 20 residue lyophilized to give Object compound (1.69 g) as a
 pink colored amorphous powder.

IR (KBr) : 2256.3, 1648.8, 1631.5, 1538.9, 1515.8,
 1440.6, 1083.8, 1047.2 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.94 (3H, d, $J=6.7\text{Hz}$), 1.09 (3H, d,
 25 $J=5.9\text{Hz}$), 1.7-2.8 (10H, m), 3.0-4.5 (19H, m), 4.6-
 5.3 (6H, m), 5.85-6.0 (1H, m), 6.72 (1H, d,
 $J=8.2\text{Hz}$), 6.82 (1H, dd, $J=1.8$ and 8.4Hz), 7.06 (1H,
 d, $J=1.7\text{Hz}$), 7.32 (1H, d, $J=8.9\text{Hz}$), 7.44 (1H, d,
 $J=9.1\text{Hz}$), 7.6-7.8 (2H, m), 7.8-8.0 (1H, br s)

30 MASS (m/z) : 901.2 ($M-\text{Na}^+$)

Elemental Analysis Calcd. for $\text{C}_{35}\text{H}_{49}\text{N}_8\text{O}_{18}\text{SNa}\cdot 6\text{H}_2\text{O}$:

C 40.70, H 5.95, N 10.85

Found : C 40.60, H 5.94, N 10.71

35 The following compound was obtained according to a
 similar manner to that of Preparation 7.

Preparation 8

IR (KBr) : 2256.3, 1648.8, 1631.5, 1538.9, 1513.8,
1267.0, 1083.8, 1047.2 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 0.96 (3H, d, $J=6.7\text{Hz}$), 1.08 (3H, d,
 $J=5.9\text{Hz}$), 1.7-2.1 (2H, m), 2.1-2.9 (7H, m), 3.1-4.6
(16H, m), 4.7-5.4 (6H, m), 6.1 (1H, br s), 6.70
(1H, d, $J=8.2\text{Hz}$), 6.75 (1H, d, $J=8.2\text{Hz}$), 6.96 (1H,
br s), 7.2-7.55 (2H, m), 7.6-7.9 (2H, m)

MASS (m/z) : 885.3 (M- Na^+)

10 Elemental Analysis Calcd. for $\text{C}_{35}\text{H}_{49}\text{N}_8\text{O}_{17}\text{SNa}\cdot 6\text{H}_2\text{O}$:
C 41.34, H 6.05, N 11.02
Found : C 41.58, H 5.99, N 10.94

Preparation 9

15 A suspension of Starting compound (1.6 g) in
dichloromethane (41 ml) was stirred with cooling at 5°C and
treated with triethylsilane (1.1 ml), followed by
trifluoroacetic acid (5.3 ml) dropwise over 30 minutes.
After warming to room temperature, the clear solution was
20 stirred for 2 hours, then poured into 450 ml of pH 6.86
phosphate buffer and adjusted to pH 8.5 with 4N-sodium
hydroxide solution. Organic solvent was removed by
evaporation and the remaining aqueous solution purified by
ODS column chromatography, eluting with aqueous acetonitrile
25 (5-20%). Object compound-containing fractions were pooled,
evaporated, and lyophilized to give Object compound (1.25 g)
as an amorphous white powder.

IR (KBr) : 1633.4, 1537.0, 1517.7, 1440.6, 1267.0 cm^{-1}

30 NMR (DMSO- d_6 , δ) : 0.95 (3H, d, $J=6.7\text{Hz}$), 1.12 (3H, d,
 $J=5.8\text{Hz}$), 1.27 (2H, d, $J=6.6\text{Hz}$), 1.28-1.70 (2H, m),
1.75-2.45 (4H, m), 2.65-3.30 (5H, m), 3.50-4.50
(11H, m), 4.60-4.90 (2H, m), 5.00 (2H, s), 5.05-
5.40 (5H, m), 6.70 (2H, d, $J=8.2\text{Hz}$), 6.76 (2H, d,
 $J=8.2\text{Hz}$), 6.96 (1H, s), 7.00-7.15 (1H, m), 7.34
35 (5H, s), 7.40-7.95 (3H, m), 8.60-8.90 (1H, m)

MASS (m/z) : 1023.3 (M- H^+)

Elemental Analysis Calcd. for $C_{43}H_{60}N_8O_{19}S \cdot 6H_2O$:

C 45.58, H 6.40, N 9.89

Found : C 45.49, H 6.24, N 9.70

5 Preparation 10

 A solution of Starting compound (3 g) in N,N-dimethylformamide (60 ml) was treated with 4-[5-[4-(7-methoxy-n-heptyloxy)phenyl]-1,3,4-thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester (2.65 g) and
10 diisopropylethylamine (0.564 ml) and stirred for 4 hours 20 minutes at room temperature. Ethyl acetate (1 l) was added and the resulting precipitate collected, washed with isopropyl ether, and dried to give Object compound (5.62 g) as a crude powder that was used directly in the next step
15 without purification.

 The following compounds [Preparations 11 to 17] were obtained according to a similar manner to that of Preparation 10.

20

Preparation 11

 The object compound was used directly in the next step without purification.

25

Preparation 12

 The object compound was used directly in the next step without purification.

Preparation 13

30

 MASS (m/z) : 1299.3 (M-Na⁺)

Preparation 14

 The object compound was used directly in the next step without purification.

35

Preparation 15

The object compound was used directly in the next step without purification.

Preparation 16

5 The object compound was used directly in the next step without purification.

Preparation 17

MASS (m/z) : 1237.3 (M-Na⁺)

10

Preparation 18

A mixture of 4-[2-(4-pentyloxyphenyl)imidazo[2,1-b]-
[1,3,4]thiadiazol-6-yl]benzoic acid (1.44 g),
1-hydroxybenzotriazole (714 mg), diisopropyl ethylamine (0.58
15 ml) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide
hydrochloride (810 mg) in N,N-dimethylformamide (50 ml) was
stirred 6 hours at room temperature, then treated with
Starting compound (2 g) and stirred overnight. Additional
N,N-dimethylformamide (20 ml) was added and stirring
20 continued for a further 5.5 hours. The clear solution was
poured into ethyl acetate (1 l) and the precipitate collected
and washed with isopropyl ether and dried to give crude
Object compound (3.58 g), which was used directly in the next
step.

25

The following compounds [Preparations 19 and 20] were
obtained according to a similar manner to that of Preparation
18.

30 Preparation 19

MASS (m/z) : 1286.3 (M-Na⁺)

Preparation 20

MASS (m/z) : 1354.4 (M-Na⁺)

35

The following compound was obtained according to a

similar manner to that of Preparation 18.

Preparation 21

IR (KBr) : 1648.8, 1631.5, 1537.0, 1513.8, 1456.0 cm^{-1}

5 NMR (DMSO- d_6 , δ) : 0.96 (3H, d, $J=7\text{Hz}$), 1.10 (3H, d,
 $J=5.6\text{Hz}$), 1.18 (6H, d, $J=6\text{Hz}$), 1.4-5.3 (38H, m),
5.88 (1H, d, $J=6\text{Hz}$), 6.71 (1H, d, $J=8\text{Hz}$), 6.75-6.80
(1H, m), 6.97 (1H, br s), 7.12 (2H, d, $J=9\text{Hz}$), 7.42
(1H, d, $J=7.6\text{Hz}$), 7.50 (1H, d, $J=9\text{Hz}$), 7.78 (2H, d,
10 $J=8.8\text{Hz}$), 7.7-8.0 (1H, br s), 7.96 (4H, s), 8.32
(1H, d, $J=8\text{Hz}$), 8.50 (1H, d, $J=7.1\text{Hz}$), 8.72 (1H,
s), 8.79 (1H, s)
MASS (m/z) : 1301.4 (M- Na^+)

15 The following compounds [Preparations 22 to 23] were
obtained according to a similar manner to that of Preparation
10.

Preparation 22

20 NMR (DMSO- d_6 , δ) : 0.95 (3H, d, $J=6.6\text{Hz}$), 6.67 (1H, d,
 $J=6.9\text{Hz}$), 6.73-6.75 (1H, m), 6.96 (1H, br s), 7.07
(2H, d, $J=8.8\text{Hz}$), 7.32 (5H, s), 7.73 (2H, d,
 $J=8.7\text{Hz}$), 7.87 (2H, d, $J=8.5\text{Hz}$), 8.06-8.14 (6H, m),
8.72 (1H, s), 8.80 (1H, d, $J=7.1\text{Hz}$)
25 MASS (m/z) : 1465.5 (M- Na^+)

Preparation 23

The object compound was used directly in the next step
without purification.

Preparation 24

To a solution of 1-N-t-butyloxycarbonyl-4-hydroxypiperidine (5.0 g) in dimethylformamide (DMF) (25 ml) was portionwise added sodium hydride (60% in oil) (1.29 g) with stirring under ice-cooling. The mixture was successively stirred at ambient temperature for 30 minutes, stirred at 60°C for 1 hour and cooled with an ice bath. To the reaction mixture was added 1,5-dibromopentane (6.72 ml), and the mixture was stirred at ambient temperature for 3 hours. The reaction solution was poured into water (100 ml) and extracted twice with a mixture of ethyl acetate (80 ml) and n-hexane (30 ml). The extract was washed with saturated aqueous sodium chloride, dried over magnesium sulfate and evaporated in vacuo. The resulting residue was chromatographed on silica gel (200 ml) eluting with a mixture of n-hexane and ethyl acetate (5:1 v/v). The fractions containing the desired compound were collected and evaporated under reduced pressure to give 4-(5-bromopentyloxy)-1-N-t-butoxycarbonylpiperidine (2.44 g).

NMR (CDCl₃, δ): 1.46 (9H, s), 1.50-1.70 (6H, m), 1.70-1.96 (4H, m), 3.00-3.15 (2H, m), 3.35-3.50 (5H, m), 3.70-3.90 (2H, m)

APCI MASS (m/z): 250 (M⁺-101)

Preparation 25

To a solution of 4-(5-bromopentyloxy)-1-N-t-butoxycarbonylpiperidine (2.44 g) in methanol (13 ml) was added 28% sodium methoxide methanol solution (14.2 ml), and the mixture was stirred under reflux for 4 hours. The reaction mixture was evaporated in vacuo. The resulting residue was chromatographed on silica gel (250 ml) eluting with a mixture of n-hexane and ethyl acetate (5:1 v/v). The fractions containing the object compound were collected and evaporated under reduced pressure to give 4-(5-methoxypentyloxy)-1-N-t-butoxycarbonylpiperidine (1.97 g).

NMR (CDCl_3 , δ): 1.45 (9H, s), 1.45-1.95 (10H, m), 3.03 (1H, dd, $J=3.47$ and 9.20Hz), 3.10 (1H, dd, $J=3.47$ and 9.20Hz), 3.44 (3H, s), 3.34-3.50 (5H, m), 3.70-3.85 (2H, m)

APCI MASS (m/z): 202 (M^+-101)

Preparation 26

To a solution of 4-(5-methoxypentyloxy)-1-N-t-butoxycarbonylpiperidine (1.97 g) in ethyl acetate (20 ml) was added 4N-hydrogen chloride ethyl acetate solution (16.3 ml), and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was evaporated in vacuo. The resulting residue was dissolved in a mixture of dichloromethane and methanol (10:1; 50 ml:5 ml). To this solution was added 1N-sodium hydroxide (5 ml) with stirring. The organic layer was separated and evaporated under reduced pressure to give 4-(5-methoxypentyloxy)piperidine (0.62 g).

NMR (CDCl_3 , δ): 1.25-1.50 (2H, s), 1.50-1.75 (6H, m), 1.90-2.10 (2H, m), 2.70-2.90 (2H, m), 2.95-3.20 (2H, m), 3.33 (3H, s), 3.35-3.50 (5H, m)

APCI MASS (m/z): 202 (M^+)

Preparation 27

A solution of 4-fluorobenzonitrile (0.38 g), 4-(5-methoxypentyloxy)piperidine (0.62 g) and potassium carbonate (0.87 g) in DMF (8 ml) was stirred at 90-95°C for 6 hours. The reaction mixture was poured into water (50 ml) and extracted twice with a mixture of ethyl acetate and n-hexane (50 ml:20 ml). The extracts were combined, washed with saturated aqueous sodium chloride, dried over magnesium sulfate and evaporated in vacuo. The resulting residue was chromatographed on silica gel (100 ml) eluting with a mixture of n-hexane and ethyl acetate (5:1 v/v - 2:1 v/v). The fractions containing the desired compound were collected and evaporated under reduced pressure

to give 4-(5-methoxypentyloxy)-N-(4-cyanophenyl)piperidine (294 mg).

NMR (CDCl_3 , δ): 1.35-1.55 (2H, s), 1.55-1.75 (5H, m),
1.85-2.05 (2H, m), 3.13 (1H, dd, $J=3.47$ and 9.20Hz),
3.17 (1H, dd, $J=3.47$ and 9.20Hz), 3.33 (3H, s),
3.35-3.75 (8H, m), 6.85 (2H, d, $J=9.01\text{Hz}$), 7.47 (2H,
d, $J=8.96\text{Hz}$)

APCI MASS (m/z): 303 (M^+)

Preparation 28

A solution of 4-(5-methoxypentyloxy)-N-(4-cyanophenyl)piperidine (294 mg) and thiosemicarbazide (0.68 g) in toluene (20 ml) and trifluoroacetic acid (10 ml) was stirred at 60-65°C for 7 hours. After cooling, the reaction mixture was poured into a mixture of water (100 ml) and ethyl acetate (200 ml) and adjusted to pH 10 with 1N-sodium hydroxide. The mixture was dissolved in a mixture of THF (50 ml) and methanol (10 ml). The organic layer was separated, washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate and evaporated in vacuo. The resulting precipitate was washed with isopropyl ether and dried in vacuo to give 2-amino-5-[4-[4-(5-methoxypentyloxy)piperidin-1-yl]phenyl]-1,3,4-thiadiazole (1.29 g).

NMR ($\text{CDCl}_3+\text{CD}_3\text{OD}$, δ): 1.30-1.50 (2H, m), 1.50-1.80 (6H, m), 1.90-2.10 (2H, m), 2.90-3.10 (2H, m), 3.34 (3H, s), 3.35-3.70 (7H, m), 6.93 (2H, d, $J=8.91\text{Hz}$), 7.63 (2H, d, $J=8.83\text{Hz}$)

APCI MASS (m/z): 377 (M^+)

Preparation 29

To a suspension of 2-amino-5-[4-[4-(5-methoxypentyloxy)piperidin-1-yl]phenyl]-1,3,4-thiadiazole (1.29 g) in ethanol (20 ml) was added ethyl 4-bromoacetylbenzoate (1.39 g) and stirred at reflux for 5 hours.

The reaction mixture was cooled and poured into diisopropyl ether (IPE) (60 ml). The resulting precipitate was collected by filtration and dried. To a suspension of the precipitate in xylene (40 ml) was added trifluoroacetic acid (4 ml), and the mixture was stirred at reflux (130°C) for 5 hours. The reaction mixture was cooled and poured into IPE (300 ml). The resulting precipitate was filtered and dried to give 4-[2-[4-[4-(5-methoxypentyloxy)piperidin-1-yl]phenyl]imidazo[2,1-b][1,3,4]thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt (2.01 g).

NMR (CDCl₃, δ): 1.42 (3H, t, J=7.12Hz), 1.45-1.75 (6H, m), 1.85-2.10 (2H, m), 2.30-2.50 (2H, m), 3.36 (3H, s), 3.35-3.55 (5H, m), 3.60-3.80 (2H, m), 4.40 (2H, q, J=7.14Hz), 7.57 (2H, d, J=8.78Hz), 7.84 (2H, d, J=8.40Hz), 7.91 (2H, d, J=8.79Hz), 8.13 (1H, s)

ESI MASS (m/z): 549 (M⁺+1)

Preparation 30

To a solution of 4-[2-[4-[4-(5-methoxypentyloxy)piperidin-1-yl]phenyl]imidazo[2,1-b][1,3,4]thiadiazol-6-yl]benzoic acid ethyl ester trifluoroacetic acid salt (2.01 g) in a mixture of methanol (40 ml) and tetrahydrofuran (20 ml) was added 4N-NaOH (20 ml), and the mixture was refluxed for 6 hours. The reaction mixture was cooled, poured into water (200 ml) and adjusted to pH 2 with conc. HCl. The resulting precipitate was collected by filtration, washed in turn with water, isopropyl alcohol (30 ml) and IPE (50 ml) to give 4-[2-[4-[4-(5-methoxypentyloxy)piperidin-1-yl]phenyl]imidazo[2,1-b][1,3,4]thiadiazol-6-yl]benzoic acid (1.28 g).

ESI MASS (m/z) (Negative): 519.2 (M⁺+1)

Preparation 31

To a solution of 4-[2-[4-[4-(5-methoxypentyloxy)-





piperidin-1-yl]phenyl]imidazo[2,1-b][1,3,4]thiadiazol-6-yl]benzoic acid (1.28 g) and 1-hydroxybenzotriazole (465 mg) in dichloromethane (50 ml) was added 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSCD·HCl) (943 mg), and the mixture was stirred overnight at ambient temperature. The reaction mixture was evaporated in vacuo. To the resulting precipitate was added water (50 ml) and filtrated. The precipitate was washed with water and IPE (50 ml) and dried under reduced pressure for 3 hours to give 4-[2-[4-[4-(5-methoxypentyloxy)piperidin-1-yl]phenyl]-imidazo[2,1-b][1,3,4]thiadiazol-6-yl]benzoic acid benzotriazol-1-yl ester (1.26 g).



IR (KBr): 1774.2, 1708.6, 1604.5, 1471.4 1365.4,
1230.4 cm^{-1}



NMR (CDCl_3 , δ): 1.30-1.80 (8H, m), 1.85-2.10 (2H, m),
3.05-3.30 (2H, m), 3.33 (3H, s), 3.35-3.55 (4H, m),
3.55-3.75 (2H, m), 6.94 (2H, d, $J=8.94\text{Hz}$), 7.30-7.60
(3H, m), 7.73 (2H, d, $J=8.79\text{Hz}$), 8.00-8.20 (4H, m),
8.30 (2H, d, $J=8.46\text{Hz}$)













ESI MASS (m/z) (Positive): 660.1 ($M^+ + \text{Na}$)





The Starting Compounds used and the Object Compounds obtained in the following Examples 1 to 30 are given in the table as below, in which the formulas of the starting compounds are in the upper column, and the formulas of the object compounds are in the lower column, respectively.





| Example No. | Formula |
|----------------|---|
| 1 |  <p>Chemical structure 1 (top): A complex molecule featuring a central core with multiple hydroxyl groups, a nitrile group, a methyl group, a sulfonate group, and a long alkoxy chain. The structure is highly branched and includes a thiazine ring system.</p> |
| |  <p>Chemical structure 1 (bottom): A complex molecule featuring a central core with multiple hydroxyl groups, an amino group, a methyl group, a sulfonate group, and a long alkoxy chain. The structure is highly branched and includes a thiazine ring system.</p> |
| 2 |  <p>Chemical structure 2 (top): A complex molecule featuring a central core with multiple hydroxyl groups, a nitrile group, a methyl group, a sulfonate group, and a long alkoxy chain. The structure is highly branched and includes a thiazine ring system.</p> |
| |  <p>Chemical structure 2 (bottom): A complex molecule featuring a central core with multiple hydroxyl groups, an amino group, a methyl group, a sulfonate group, and a long alkoxy chain. The structure is highly branched and includes a thiazine ring system.</p> |






| Example No. | Formula |
|-------------|---|
| 3 13 |  |
| |  |




| Example No. | R | X |
|-------------|--|----|
| 3 |  | Na |
| 4 |  | Na |





| Example No. | R | X |
|-------------|--|---|
| 5 |  | Na |
| 6 |  | Na |
| 7 |  |  |
| 8 |  |  |
| 9 |  | Na |
| 10 |  | Na |
| 11 |  | Na |
| 12 |  |  |
| 13 |  | Na |






| Example No. | Formula |
|----------------|---|
| 14 |  <p>Chemical structure of a complex molecule, likely a derivative of a natural product. It features a central core with multiple hydroxyl groups, a sulfonamide group, and a long alkoxy chain. The structure is highly branched and contains several amide and ester linkages.</p> |
| |  <p>Chemical structure of a complex molecule, similar to the one above, but with a different side chain. It features a central core with multiple hydroxyl groups, a sulfonamide group, and a long alkoxy chain. The structure is highly branched and contains several amide and ester linkages.</p> |
| 15 |  <p>Chemical structure of a complex molecule, similar to the ones above, but with a different side chain. It features a central core with multiple hydroxyl groups, a sulfonamide group, and a long alkoxy chain. The structure is highly branched and contains several amide and ester linkages.</p> |
| |  <p>Chemical structure of a complex molecule, similar to the ones above, but with a different side chain. It features a central core with multiple hydroxyl groups, a sulfonamide group, and a long alkoxy chain. The structure is highly branched and contains several amide and ester linkages.</p> |





| Example No. | Formula |
|-------------|--|
| 16 |  <p>Chemical structure of a complex molecule. It features a central core with multiple hydroxyl groups and amide linkages. A benzyl group is attached to the core. A sulfonate group (O_3SO^-) is attached to the core. A long alkoxy chain ($\text{O}(\text{CH}_2)_3\text{OCH}_2\text{CH}_3$) is attached to the core. The molecule is shown as a zwitterion with a protonated tertiary amine (H^+N^+) and a sulfonate anion (O_3SO^-).</p> |
| |  <p>Chemical structure of a complex molecule, similar to the one above, but with a different alkoxy chain ($\text{O}(\text{CH}_2)_3\text{OCH}_2\text{CH}_3$) and a different sulfonate group (HO_3SO).</p> |
| 17 |  <p>Chemical structure of a complex molecule, similar to the ones above, but with a different alkoxy chain ($\text{O}(\text{CH}_2)_8\text{OCH}_3$) and a different sulfonate group (HO_3SO).</p> |
| |  <p>Chemical structure of a complex molecule, similar to the ones above, but with a different alkoxy chain ($\text{O}(\text{CH}_2)_8\text{OCH}_3$) and a different sulfonate group (HO_3SO).</p> |





| Example No. | Formula |
|-------------|---|
| 18 |  |
| |  |
| 19 |  |
| | <div data-bbox="527 1407 617 1438">major</div> <div data-bbox="1071 1386 1169 1417">minor</div> <div data-bbox="544 1459 787 1743"></div> <div data-bbox="1023 1491 1274 1711"></div> |



| Example No. | Formula |
|-------------|---|
| 20 |  <p>The structure shows a complex polycyclic molecule with several hydroxyl groups. It features a sulfonate group (NaO₂SO) and a Boc-protected amine (NH-Boc). The molecule is highly branched with various functional groups including amides and esters.</p> |
| 21 |  <p>This structure is similar to the one in Example 20, but it lacks the sodium sulfonate group and instead has a sulfonic acid group (HO₂SO). It also contains a Boc-protected amine and multiple hydroxyl groups.</p> |
| 21 |  <p>This structure is more complex than the previous ones, featuring a sulfonic acid group (HO₂SO) and a Boc-protected amine. It also includes a long chain with a sulfonate group (O(CH₂)₃OCH₃) and a dimethylamino group (N(CH₃)₂).</p> |

| Example No. | Formula |
|----------------|---|
| 22 |  A complex molecule featuring a central core with multiple hydroxyl groups, a sulfonate group, and a long chain with a thiazine ring and a piperidine ring. The structure is highly branched and contains several functional groups. |
| |  A complex molecule featuring a central core with multiple hydroxyl groups, a sulfonate group, and a long chain with a thiazine ring and a piperidine ring. The structure is highly branched and contains several functional groups. |
| 23 |  A complex molecule featuring a central core with multiple hydroxyl groups, a sulfonate group, and a long chain with a thiazine ring and a piperidine ring. The structure is highly branched and contains several functional groups. |
| |  A complex molecule featuring a central core with multiple hydroxyl groups, a sulfonate group, and a long chain with a thiazine ring and a piperidine ring. The structure is highly branched and contains several functional groups. |

| Example No. | Formula |
|-------------|---|
| 24 |  |
| | <div data-bbox="542 701 639 732">major</div> <div data-bbox="1062 722 1159 753">minor</div> <div data-bbox="542 764 818 995"></div> <div data-bbox="980 785 1256 1016"></div> |
| 25 |  |
| |  |

| Example No. | Formula |
|-------------|--|
| 26 |  |
| |  |
| 27 |  |
| |  |

| Example No. | Formula |
|-------------|--|
| 28 |  <p>Chemical structure of a complex molecule. It features a central core with multiple hydroxyl groups, a sulfonate group (HO₃SO-), and a long alkyl chain (CH₂)₁₄CH₃. The structure is highly branched and includes several amide and ester linkages.</p> |
| |  <p>Chemical structure of a complex molecule, similar to the one above, but with a different substitution pattern. It features a central core with multiple hydroxyl groups, a sulfonate group (HO₃SO-), and a long alkyl chain (CH₂)₁₄CH₃. The structure is highly branched and includes several amide and ester linkages.</p> |
| 29 |  <p>Chemical structure of a complex molecule, similar to the ones above, but with a different substitution pattern. It features a central core with multiple hydroxyl groups, a sulfonate group (HO₃SO-), and a long alkyl chain (CH₂)₁₄CH₃. The structure is highly branched and includes several amide and ester linkages.</p> |
| |  <p>Chemical structure of a complex molecule, similar to the ones above, but with a different substitution pattern. It features a central core with multiple hydroxyl groups, a sulfonate group (NaO₃SO-), and a long alkyl chain (CH₂)₁₄CH₃. The structure is highly branched and includes several amide and ester linkages.</p> |

| Example No. | Formula |
|----------------|--|
| 30 |  <p>Chemical structure of a complex molecule. It features a central core with multiple hydroxyl groups, a methyl group, a long alkyl chain (CH₂)₁₄CH₃, and a sulfonate group (HO₃SO-). The structure is highly branched and contains several amide and ester linkages.</p> |
| |  <p>Chemical structure of a complex molecule, similar to the one above, but with a different substituent on the left side. It features a central core with multiple hydroxyl groups, a methyl group, a long alkyl chain (CH₂)₁₄CH₃, and a sulfonate group (NaO₃SO-). The structure is highly branched and contains several amide and ester linkages.</p> |

Example 1

A solution of crude Starting compound (5.6 g) in methanol (168 ml) - water (336 ml) was treated with cobalt chloride hexahydrate (3.08 g) and the mixture stirred to give a pink colored solution. Sodium borohydride (2.46 g) was then added portionwise over 1 hour. Additional cobalt chloride (1.54 g) was added followed by sodium borohydride (1.23 g, portionwise). After a total reaction time of 2 hours 50% aqueous acetonitrile (600 ml) was added and insoluble material removed by filtration. The filtrate was evaporated to remove organic solvent and sufficient 1N-sodium hydroxide was added to the remaining aqueous layer to effect solution. This clear aqueous solution was then purified by ODS column chromatography eluting with aqueous acetonitrile. Object compounds-containing fractions were pooled, evaporated, and lyophilized to give Object compound (1.4 g) as an amorphous white powder.

IR (KBr) : 1658.5, 1635.3, 1546.6, 1529.3, 1517.7,
1444.4, 1257.4 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.96 (3H, d, $J=6.8\text{Hz}$), 1.10 (3H, d, $J=6\text{Hz}$), 1.30-1.60 (8H, m), 1.60-2.50 (15H, m), 3.21 (3H, s), 2.80-5.40 (29H, m), 6.74 (1H, d, $J=8.2\text{Hz}$), 6.80-6.85 (1H, m), 7.07 (1H, br s), 7.14 (2H, d, $J=8.9\text{Hz}$), 7.40-7.80 (4H, m), 7.97 (2H, d, $J=8.8\text{Hz}$), 8.09 (4H, ABq like, br m), 8.20-8.30 (1H, m), 8.80-8.90 (1H, m)

MASS (m/z) : 1313.3 ($M-H^+$)

Elemental Analysis Calcd. for $\text{C}_{58}\text{H}_{78}\text{N}_{10}\text{O}_{21}\text{S}_2 \cdot 9\text{H}_2\text{O}$:

C 47.34, H 6.16, N 9.52

Found : C 47.42, H 6.26, N 9.47

The following compounds [Examples 2 to 13] were obtained according to a similar manner to that of Example 1.

Example 2

IR (KBr) : 1648.8, 1631.5, 1538.9, 1515.8, 1442.5,
1257.4 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.98 (3H, d, $J=6.7\text{Hz}$), 1.24 (3H, d,
5 $J=5.6\text{Hz}$), 1.40-1.60 (8H, m), 1.60-2.65 (15H, m),
2.80-5.50 (27H, m), 3.21 (3H, s), 3.30 (2H, t,
 $J=6.3\text{Hz}$), 6.72 (1H, d, $J=8.1\text{Hz}$), 6.78 (1H, dd,
 $J=1.6$ and 8.3Hz), 7.00 (1H, d, $J=1.6\text{Hz}$), 7.13 (2H,
d, $J=8.9\text{Hz}$), 7.46 (1H, d, $J=8.1\text{Hz}$), 7.60-7.90 (2H,
m), 7.97 (2H, d, $J=8.7\text{Hz}$), 8.04-8.14 (4H, m), 8.24-
10 8.27 (1H, m), 8.70-9.00 (2H, m)

MASS (m/z) : 1297.3 ($M-H^+$)

Elemental Analysis Calcd. for $\text{C}_{58}\text{H}_{78}\text{N}_{10}\text{O}_{20}\text{S}_2 \cdot 7.5\text{H}_2\text{O}$:

C 48.56, H 6.53, N 9.76

Found : C 48.56, H 6.31, N 9.63

15

Example 3

IR (KBr) : 1633.4, 1517.7, 1444.4, 1257.4 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.97 (3H, d, $J=6.8\text{Hz}$), 1.13 (3H, d,
20 $J=5.7\text{Hz}$), 1.20-1.65 (10H, m), 1.65-2.65 (15H, m),
2.70-5.50 (27H, m), 3.21 (3H, s), 4.07 (2H, t,
 $J=6.5\text{Hz}$), 6.71 (1H, d, $J=8\text{Hz}$), 6.75-6.80 (1H, m),
6.98 (1H, d, $J=1.6\text{Hz}$), 7.13 (2H, d, $J=8.9\text{Hz}$), 7.46
(1H, d, $J=8\text{Hz}$), 7.55-7.85 (2H, m), 7.97 (2H, d,
 $J=8.8\text{Hz}$), 8.07 (4H, ABq, $J=10.8\text{Hz}$), 8.09-8.13 (1H,
25 m), 8.79 (1H, d, $J=7.9\text{Hz}$), 8.55-9.00 (1H, br s)

MASS (m/z) : 1311.3 ($M-H^+$)

Elemental Analysis Calcd. for $\text{C}_{59}\text{H}_{80}\text{N}_{10}\text{O}_{20}\text{S}_2 \cdot 10\text{H}_2\text{O}$:

C 47.45, H 6.75, N 9.38

Found : C 47.68, H 6.27, N 9.21

30

Example 4

IR (KBr) : 1648.8, 1631.5, 1540.8, 1513.8, 1452.1 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.95 (3H, d, $J=6.6\text{Hz}$), 1.07 (3H, d,
35 $J=6\text{Hz}$), 1.1-2.7 (21H, m), 2.7-5.5 (32H, m), 6.68-
6.74 (2H, m), 6.9-6.94 (1H, m), 7.13 (2H, d,
 $J=8.9\text{Hz}$), 7.2-7.5 (1H, m), 7.5-7.8 (2H, m), 7.97

5 Example 5

Example 6

Example 7

IR (KBr) : 1635.3, 1606.4, 1531.2, 1496.5, 1444.4,
1419.4 cm^{-1}
NMR (DMSO- d_6 , δ) : 0.97 (3H, d, $J=6.8\text{Hz}$), 1.11 (3H, d,
35 $J=5.7\text{Hz}$), 1.05-1.04 (5H, m), 1.50-5.30 (52H,
complex m), 6.67 (1H, d, $J=5.7\text{Hz}$), 6.73-6.80 (1H,

m), 7.01 (1H, d, J=1.6Hz), 7.08 (2H, d, J=9Hz),
 7.4-7.8 (3H, m), 7.85 (2H, d, J=8.7Hz), 8.07 (4H,
 ABq, J=9Hz), 8.31 (1H, d, J=6.9Hz), 8.71 (1H, s),
 8.91 (1H, d, J=7.4Hz)

5 MASS (m/z) : 1319.4 (M-H⁺)

Elemental Analysis Calcd. for C₆₀H₈₀N₁₂O₁₈S₂·9H₂O :

C 48.57, H 6.66, N 11.33

Found : C 48.77, H 6.54, N 11.25

10 Example 8

IR (KBr) : 1635.3, 1529.3, 1519.6, 1467.6, 1446.4,
 1257.4 cm⁻¹

15 NMR (DMSO-d₆, δ) : 0.91 (3H, t, J=7Hz), 0.96 (3H, d,
 J=8.3Hz), 1.12 (3H, d, J=5.6Hz), 1.2-2.6 (17H, m),
 2.6-5.4 (29H, m), 6.71 (1H, d, J=8Hz), 6.77 (1H, br
 d, J=8Hz), 6.98 (1H, d, J=1.7Hz), 7.14 (2H, d,
 J=8.9Hz), 7.45 (1H, d, J=8.5Hz), 7.4-7.8 (3H, m),
 7.90 (2H, d, J=8.8Hz), 8.05 (4H, s), 8.1-8.3 (1H,
 s), 8.64 (1H, d, J=6.9Hz), 8.85 (1H, s)

20 MASS (m/z) : 1278.3 (M-H⁺)

Elemental Analysis Calcd. for C₅₇H₇₃N₁₁O₁₉S₂·9H₂O :

C 47.46, H 6.36, N 10.68

Found : C 47.58, H 6.17, N 10.62

25 Example 9

IR (KBr) : 3361.3, 2937.1, 1635.3, 1523.5, 1461.8,
 1251.6 cm⁻¹

30 NMR (DMSO-d₆, δ) : 0.97 (3H, d, J=6.8Hz), 1.10 (3H, d,
 J=5.9Hz), 1.2-5.3 (49H, m), 6.67-6.80 (2H, m), 7.01
 (1H, d, J=1.6Hz), 7.15 (2H, d, J=9Hz), 7.4-7.8 (3H,
 m), 7.88 (2H, d, J=8.8Hz), 7.96 (4H, s), 8.35 (1H,
 d, J=8.3Hz), 8.7-8.8 (2H, m), 8.86 (1H, s)

API-ES MASS (Negative) : 1290.3 (M-H⁺)

Elemental Analysis Calcd. for C₅₈H₇₃N₁₁O₁₉S₂·8H₂O :

C 48.29 H 6.26, N 10.53

35

Found : C 48.49 H 6.24, N 10.73

Example 10

IR (KBr) : 1637.3, 1523.5, 1459.9, 1238.1 cm^{-1}

MASS (m/z) : 1358.4 ($\text{M}-\text{H}^+$)

5 Example 11

IR (KBr) : 3357.5, 1631.5, 1517.7, 1465.6, 1450.2,
1241.9 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 0.98 (3H, d, $J=6.8\text{Hz}$), 1.10 (3H, d,
10 $J=6\text{Hz}$), 1.18 (6H, d, $J=6\text{Hz}$), 1.5-2.7 (11H, m), 2.8-
5.4 (33H, m), 6.71 (1H, d, $J=8.2\text{Hz}$), 6.78 (1H, dd,
 $J=8$ and 1.6Hz), 7.01 (1H, d, $J=1.6\text{Hz}$), 7.12 (2H, d,
 $J=9\text{Hz}$), 7.44 (1H, d, $J=8.7\text{Hz}$), 7.6-7.9 (1H, m),
15 7.67 (1H, d, $J=8\text{Hz}$), 7.78 (2H, d, $J=8.8\text{Hz}$), 7.96
(4H, s), 8.35 (1H, d, $J=7\text{Hz}$), 7.6-8.8 (1H, br s),
8.75 (1H, d, $J=7\text{Hz}$), 8.81 (1H, s)

API-ES MASS (Negative) : 1305.3($\text{M}-\text{H}^+$)

Elemental Analysis Calcd. for $\text{C}_{58}\text{H}_{74}\text{N}_{12}\text{O}_{19}\text{S}_2 \cdot 8\text{H}_2\text{O}$:

C 48.05, H 6.24, N 11.55

Found : C 47.99, H 6.25, N 11.58

20

Example 12

IR (KBr) : 1631.5, 1510.0, 1446.4, 1234.2 cm^{-1}

NMR ($\text{DMSO}-d_6$, δ) : 0.96 (3H, d, $J=6.7\text{Hz}$), 1.09 (3H, d,
25 $J=5.8\text{Hz}$), 1.2-2.65 (15H, m), 2.7-5.3 (41H, m), 3.21
(3H, s), 3.30 (2H, t, $J=6.4\text{Hz}$), 3.85 (2H, t,
 $J=6.5\text{Hz}$), 6.70 (1H, d, $J=8.2\text{Hz}$), 6.74-6.80 (1H, m),
6.83 (2H, d, $J=9\text{Hz}$), 6.94 (2H, d, $J=9\text{Hz}$), 6.99 (1H,
s), 7.01 (2H, d, $J=8.8\text{Hz}$), 7.44 (1H, d, $J=8.6\text{Hz}$),
7.6-7.9 (2H, m), 7.80 (2H, d, $J=8.7\text{Hz}$), 8.1-8.3
30 (2H, m), 8.37 (1H, d, $J=7.7\text{Hz}$)

MASS (m/z) : 1297.5 ($\text{M}-\text{Na}^+$)

Elemental Analysis Calcd. for $\text{C}_{60}\text{H}_{86}\text{N}_{10}\text{O}_{20}\text{S} \cdot 7\text{H}_2\text{O}$:

C 50.55, H 7.07, N 9.83

Found : C 50.68, H 7.08, N 9.82

35

Example 13

IR (KBr) : 1648.8, 1631.5, 1540.8, 1511.9, 1454.1,
1238.1 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.8-1.3 (18H, m), 1.5-2.5 (24H, m),
2.61 (4H, br s), 2.8-5.4 (27H, m), 6.70 (1H, d,
J=8.1Hz), 6.77 (1H, br d, J=10Hz), 6.92 (2H, d,
J=9Hz), 7.00 (1H, d, J=1.6Hz), 7.42 (1H, d,
J=8.6Hz), 7.5-7.7 (2H, m), 7.76 (2H, d, J=8.6Hz),
8.30 (1H, d, J=7.1Hz), 8.44 (1H, d, J=6.9Hz), 8.46-
9.00 (1H, br s)

MASS (m/z) : 1241.3 (M-H⁺)

Elemental Analysis Calcd. for $\text{C}_{58}\text{H}_{86}\text{N}_{10}\text{O}_{18}\text{S} \cdot 10\text{H}_2\text{O}$:

C 48.94, H 7.50, N 9.84

Found : C 49.19, H 7.33, N 9.73

Example 14

A solution of Starting compound (150 mg) in N,N-dimethylformamide (1.5 ml) was treated with diisopropylethylamine (166.5 mg) and ethyl formimidate hydrochloride (64.8 mg) and stirred 2 days at room temperature. Additional ethyl formimidate hydrochloride (39 mg) was added and stirring continued a further 3 hours 15 minutes. The reaction mixture was diluted with water and purified by ODS column chromatography, eluting with aqueous acetonitrile. Product-containing fractions were pooled, evaporated, and lyophilized to give Object compound as an amorphous white powder.

IR (KBr) : 1658.5, 1635.3, 1444.4, 1257.4 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.97 (3H, d, J=6.7Hz), 1.10 (3H, d, J=6.1Hz), 1.20-1.60 (8H, m), 1.60-2.50 (15H, m),
3.21 (3H, s), 2.80-5.30 (27H, m), 6.71 (1H, d, J=8.1Hz), 6.78 (1H, d, J=6Hz), 7.00 (1H, br s),
7.14 (2H, d, J=8.9Hz), 7.40-7.84 (4H, m), 7.84 (1H, s), 7.97 (2H, d, J=8.8Hz), 8.08 (4H, ABq, J=8.9Hz),
8.30-8.40 (2H, m), 8.90-9.10 (2H, m)

MASS (m/z) : 1325.4 (M-H⁺)

Elemental Analysis Calcd. for $\text{C}_{58}\text{H}_{79}\text{N}_{11}\text{O}_{19}\text{S}_2 \cdot 8\text{H}_2\text{O}$:

C 48.29, H 6.64, N 10.68

Found : C 48.01, H 6.34, N 10.38

The following compounds [Examples 15 to 17] were
 5 obtained according to a similar manner to that of Example 14.

Example 15IR (KBr) : 1658, 1635, 1628, 1444, 1257 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.97 (3H, d, $J=6.7\text{Hz}$), 1.11 (3H, d,
 10 $J=6.1\text{Hz}$), 1.25-1.60 (8H, m), 1.60-2.50 (15H, m),
 2.05 (3H, s), 3.21 (3H, s), 2.80-5.30 (27H, m),
 6.71 (1H, d, $J=8.1\text{Hz}$), 6.77 (1H, d, $J=8\text{Hz}$), 7.00
 (1H, br s), 7.13 (2H, d, $J=8.9\text{Hz}$), 7.30-7.90 (4H,
 m), 7.97 (2H, d, $J=8.7\text{Hz}$), 8.08 (4H, ABq, $J=8.8\text{Hz}$),
 15 8.50-9.00 (4H, m)

MASS (m/z) : 1362.3 ($M-\text{Na}^+$)Elemental Analysis Calcd. for $\text{C}_{59}\text{H}_{81}\text{N}_{11}\text{O}_{19}\text{S}_2 \cdot 9\text{H}_2\text{O}$:

C 48.06, H 6.77, N 10.45

Found : C 48.02, H 6.48, N 10.11

20

Example 16IR (KBr) : 1643.1, 1633.4, 1535.1, 1513.8, 1442.5,
 1249.6 cm^{-1}

NMR (DMSO- d_6 , δ) : 0.97 (3H, d, $J=6.8\text{Hz}$), 1.1-1.16 (3H,
 25 m), 1.12 (3H, t, $J=7\text{Hz}$), 1.4-2.6 (12H, m), 2.8-5.2
 (34H, m), 6.71 (1H, d, $J=8\text{Hz}$), 6.78 (1H, dd, $J=8$
 and 2Hz), 7.00 (1H, d, $J=2\text{Hz}$), 7.08 (2H, d,
 $J=8.8\text{Hz}$), 7.45 (1H, d, $J=8.9\text{Hz}$), 7.6-7.8 (2H, m),
 7.73 (2H, d, $J=8.8\text{Hz}$), 7.87 (2H, d, $J=8.5\text{Hz}$), 8.0-
 30 8.2 (6H, m), 8.28 (1H, d, $J=7\text{Hz}$), 8.91 (1H, d,
 $J=7.6\text{Hz}$), 8.5-9.05 (1H, br s)

MASS (m/z) : 1331.2 ($M-\text{H}^+$)Elemental Analysis Calcd. for $\text{C}_{61}\text{H}_{76}\text{N}_{10}\text{O}_{20}\text{S}_2 \cdot 10\text{H}_2\text{O}$:

C 48.41, H 6.39, N 9.25

35

Found : C 48.63, H 6.13, N 9.13

Example 17

IR (KBr) : 1631.5, 1537.0, 1510.0, 1448.3, 1234.2 cm^{-1}

NMR ($\text{DMSO-d}_6 + \text{D}_2\text{O}$, δ) : 0.96 (3H, d, $J=6.7\text{Hz}$), 1.05-1.15
(3H, m), 1.2-3.0 (33H, m), 3.15 (3H, s), 3.29 (2H,
5 t, $J=6.4\text{Hz}$), 3.88 (2H, t, $J=6.4\text{Hz}$), 3.6-4.5 (14H,
m), 4.7-4.85 (2H, m), 6.73-7.04 (9H, m), 7.75-7.9
(2H, m)

MASS (m/z) : 1311.4 (M-H^+)

Elemental Analysis Calcd. for $\text{C}_{61}\text{H}_{88}\text{N}_{10}\text{O}_{20}\text{S} \cdot 10\text{H}_2\text{O}$:

C 49.05, H 7.29, N 9.38

10 Found : C 48.78, H 6.83, N 9.27

15

20

25

Example 18

To a solution of a mixture of the starting compound (18) (5.4 g), 2-oxo-1,3-diacetoxyp propane (4.85 g) and acetic acid (0.78 ml) in a mixture of methanol (80 ml) and dimethylformamide (40ml) was added sodium cyanoborohydride (1.71 g) with stirring at ambient temperature, and the mixture was stirred at the same temperature overnight. The reaction mixture was concentrated in vacuo. To the resulting residue was added pH 6.86 standard buffer solution (100 ml) and acetonitrile (20 ml), and the solution was adjusted pH to 8.5 with 1N sodium hydroxide. The solution was subjected to column chromatography on ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (400 ml) eluting in turn with water, 20% acetonitrile in water and 25% acetonitrile in water. The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (18) (4.44 g).

IR (KBr): 1632, 1516, 1452, 1273, 1248 cm^{-1}

NMR (DMSO- d_6 +D $_2$ O, δ): 0.98 (3H, d, $J=6.88\text{Hz}$), 1.11 (3H, d, $J=5.64\text{Hz}$), 1.36 (9H, s), 1.40-2.00 (6H, m), 2.50-2.95 (4H, m), 3.30-3.55 (2H, m), 3.65-4.45 (16H, m), 4.70-4.85 (2H, m), 5.36 (1H, s), 6.71 (1H, d, $J=8.05\text{Hz}$), 6.77 (1H, d, $J=8.29\text{Hz}$), 6.99 (1H, s), 7.30-7.45 (5H, m)

APCI MASS (Positive): (m/z) 1175.4 (M^+ +Na)

Elemental analysis Calcd. for $\text{C}_{50}\text{H}_{72}\text{N}_8\text{O}_{21}\text{S} \cdot 5\text{H}_2\text{O}$

: C 46.80, H 6.52, N 8.73

Found : C 47.06, H 6.44, N 8.54

Example 19

A solution of the starting compound (19) (4.42 g) and 10% palladium on carbon (50% including water) (3.0 g) in a mixture of methanol (90 ml) and water (80 ml) was hydrogenated under an atmospheric pressure of hydrogen with stirring at ambient temperature for 8 hours. To the reaction mixture was added 10% palladium hydroxide on carbon (50% including water) (4.0 g),

and, the mixture was hydrogenated under an atmospheric pressure of hydrogen with stirring at ambient temperature for 16 hours. The catalyst was filtered off and washed with a mixture of methanol and water (1:1 v/v) (50 ml), and the filtrate and washes were combined. To the solution was dropwise added allyloxycarbonyl chloride (1.72 ml) in tetrahydrofuran (4 ml) adjusting pH to 8.5-10.0 with 1N sodium hydroxide with stirring on an ice-bath. The mixture was stirred at the same temperature for 2 hours and adjusted pH to 8.0 with 1N hydrochloric acid. The solution was subjected to column chromatography on ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (400 ml) eluting with 10% acetonitrile in water and then with 20% acetonitrile in water. The first fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the major object compound (50) (0.47 g). The second fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the minor object compound (50) (2.91 g).

major object compound (50)

IR (KBr): 1761, 1672, 1635, 1512, 1450 cm^{-1}

NMR (DMSO- d_6 +D $_2$ O, δ): 0.96 (3H, d, $J=6.79\text{Hz}$), 1.00-1.15 (3H, m), 1.35 (9H, s), 1.45-2.50 (9H, m), 2.80-3.40 (6H, m), 3.70-4.60 (16H, m), 4.65-4.90 (4H, m), 5.10-5.45 (4H, m), 5.80-6.10 (2H, m), 6.71 (1H, d $J=8.23\text{Hz}$), 6.77 (1H, d. $J=9.01\text{Hz}$), 6.98 (1H, s)

ESI MASS (Positive): (m/z) 1277.2 (M^+ +Na)

minor object compound (50)

NMR (DMSO- d_6 +D $_2$ O, δ): 0.96 (3H, d, $J=6.57\text{Hz}$), 1.06 (3H, d $J=4.94\text{Hz}$), 1.36 (9H, s), 1.45-2.45 (8H, m), 2.75-3.70 (9H, m), 3.75-4.60 (12H, m), 4.69 (2H, d $J=5.19\text{Hz}$), 4.70-4.90 (2H, m), 5.05-5.50 (3H, m), 5.80-6.10 (1H, m), 6.91 (1H, d, $J=8.29\text{Hz}$), 7.10 (1H,

d, J=8.31Hz), 7.43 (1H, S)

ESI MASS (Positive): (m/z) 1193.3 (M⁺+Na)

Example 20

A suspension of the object compound (20) (1.73 g) in dichloromethane (40 ml) was stirred with cooling at 5 °C and treated with triethylsilane (1.1 ml), followed by trifluoroacetic acid (3.19 ml) dropwise over 30 minutes. After warming to room temperature, the clear solution was stirred for 2 hours, and then poured into a mixture of saturated aqueous sodium hydrogen carbonate (100 ml) and pH 6.86 standard buffer (100 ml). Organic solvent was removed by evaporation, and the remaining aqueous solution purified by ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (200 ml) column chromatography, eluting with aqueous acetonitrile (10-20%). The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (20) (1.10 g).

IR (KBr): 1761, 1668, 1647, 1539, 1512, 1437 cm⁻¹

NMR (DMSO-d₆+D₂O, δ): 0.95 (3H, d, J=6.77Hz), 1.18 (3H, d, J=4.94Hz), 1.40-2.40 (7H, m), 2.70-3.40 (4H, m), 3.60-4.60 (17H, m), 4.69 (2H, d, J=5.37Hz), 4.70-4.90 (2H, m), 5.10-5.50 (4H, m), 5.80-6.20 (2H, m), 6.89 (1H, d), 7.08 (1H, d, J=8.21Hz)

ESI MASS (Positive): (m/z) 1155.4 (M⁺+Na)

Elemental analysis Calcd. for C₄₆H₆₈N₈O₂₃S·4H₂O

: C 45.84, H 6.36, N 9.30

Found : C 45.85, H 6.33, N 9.16

Example 21

A solution of the starting compound (21) (0.43 g) in dimethylformamide (4 ml) was treated with 4-[2-[4-[4-(5-methoxypentyloxy)piperidin-1-yl]phenyl]imidazo[2,1-b][1,3,4]thiadiazol-6-yl]benzoic acid benzotriazol-1-yl ester (194 mg) and diisopropylethylamine (78.4 μl) and stirred

for 5 hours at room temperature. Ethylacetate (50 ml) was added, and the resulting precipitate collected, washed with isopropylether, and dried to give the object compound (21) (610.6 mg) as a crude powder, that was used directly in the next reaction without purification.

Example 22

To a solution of the starting compound (22) (610.6 mg) in a mixture of methanol (10 ml) and tetrahydrofuran (25 ml) were successively added triphenylphosphine (32 mg), tetrakis(triphenylphosphine)palladium(0) (35 mg) and morpholine (106 μ l) with stirring, and the mixture was stirred at ambient temperature for 3.5 hours. Ethyl acetate (100 ml) was added, and the resulting precipitate collected, washed with isopropylether, and dried to give a crude pale yellow powder (535 mg). The crude powder was dissolved sodium hydroxide aqueous solution and subjected to column chromatography on ODS (YMC-gel ODS-AM-S-50 (Trademark: prepared by YMC Co. Ltd.)) (37% acetonitrile aqueous solution). The fractions containing the object compound were combined, and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (22) (293.7 mg).

IR(KBr): 3355.5, 1633.4, 1608.3, 1529.3, 1517.7, 1463.7, 1444.4, 1267.0, 1230.4 cm^{-1}

NMR(DMSO- d_6 , δ): 0.98(d, 3H, $J=6.7\text{Hz}$), 1.10(d, 3H, $J=5.6\text{Hz}$), 1.2-5.6 (m, 65H), 6.71(d, 1H, $J=8.1\text{Hz}$), 6.78(d, 1H, $J=9.7\text{Hz}$), 7.00(s, 1H), 7.09(d, 2H, $J=9.1\text{Hz}$), 7.75(d, 2H, $J=8.7\text{Hz}$), 7.95(s, 4H), 7.3-8.7(m, 7H), 8.79(s, 1H)

MASS: (m/z) 1465.5 (M-H) $^-$

Elemental analysis Calcd. for $\text{C}_{66}\text{H}_{90}\text{N}_{12}\text{O}_{22}\text{S}_2 \cdot 7\text{H}_2\text{O}$:

C 49.74, H 6.58, N 10.55

Found : C 49.72, H 6.43, N 10.40

Example 23

A solution of the starting compound (10 g) in a mixture

of methanol (500 ml) and water (100 ml) was treated with cobalt (II) chloride hexahydrate (9.43 g) and then stirred to give a pink solution. Sodium borohydride (7.5 g) was then added portionwise and stirred for 1 hour at ambient temperature. The reaction mixture was filtered through a bed of celite, washing with a mixture of methanol (100 ml) and water (20 ml). The ice-cooled filtrate was then treated dropwise with a solution of allyloxycarbonyl chloride (1.46 ml) in tetrahydrofuran (10 ml), keeping pH 8.0-9.5 with 1N sodium hydroxide and then stirred for 1 hour at the same temperature. The reaction mixture was evaporated in vacuo (about 200 ml) and added 1N sodium hydroxide (60 ml), and then the mixture was stayed in the refrigerator overnight. To the solution was added water (200 ml), and the mixture was purified by ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark : prepared by Daiso Co. Ltd.)) (200 ml) column chromatography, eluting with aqueous acetonitrile (5-20%). The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (23) (8.58 g).

IR (KBr): 1670, 1633, 1516, 1443, 1269 cm^{-1}

NMR (DMSO- d_6 +D $_2$ O, δ) : 0.97 (3H, d, $J=6.75\text{Hz}$), 1.08 (3H, d, $J=5.52\text{Hz}$), 1.35 (9H, s), 1.40-2.00 (6H, m), 2.10-2.50 (3H, m), 2.80-3.40 (4H, m), 3.65-4.50 (14H, m), 4.65-4.85 (2H, m), 5.05-5.35 (2H, m), 5.70-6.00 (1H, m), 6.72 (1H, d, $J=8.12\text{Hz}$), 6.78 (1H, d, $J=10.1\text{Hz}$)

ESI MASS (Positive): (m/z) 1119.3 ($M^+ + \text{Na}$)

Elemental analysis Calcd. for $\text{C}_{45}\text{H}_{67}\text{N}_8\text{O}_{21}\text{SNa} \cdot 5\text{H}_2\text{O}$:

C 44.52, H 6.37, N 9.44

Found : C 44.59, H 6.43, N 9.47

Example 24

A suspension of the starting compound (24) (8.5 g) in dichloromethane (180 ml) was stirred with cooling at 5 $^{\circ}\text{C}$ and treated with triethylsilane (6.2 ml), followed by trifluoroacetic acid (17.9 ml) dropwise over 30 minutes.

After warming to room temperature, the clear solution was stirred for 2 hours, then poured into a mixture of saturated aqueous sodium hydrogen carbonate (200 ml) and pH 6.86 standard buffer (200 ml). Organic solvent was removed by evaporation, and the remaining aqueous solution purified by ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (200 ml) column chromatography, eluting with aqueous acetonitrile (5-20%). The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (24) (5.53 g).

NMR (DMSO-d₆+D₂O, δ): 0.97 (3H, d, J=6.64Hz), 1.15 (3H, d, J=5.52Hz), 1.30-1.70 (3H, m), 1.80-2.50 (6H, m), 2.70-4.00 (14H, m), 4.20-4.60 (8H, m), 4.70-4.90 (2H, m), 5.10-5.40 (2H, m), 5.70-6.10 (1H, m), 6.70-6.90 (2H, m), 7.06 (1H, s)

ESI MASS (Positive): (m/z) 997.3 (M⁺+Na)

Example 25

A solution of the starting compound (25) (0.5 g) in dimethylformamide (10 ml) was treated with 4-[5-[4-[4-(cis-4-methylcyclohexyl)piperazinyl]phenyl]-1,3,4-thiadiazol-2-yl]benzoic acid benzotriazol-1-yl ester (0.3 g) and diisopropylethylamine (0.13 ml) and stirred for 20 hours at room temperature. Ethylacetate (100 ml) was added and the resulting precipitate collected, washed with ethylacetate, and dried to give the object compound (25) (0.5 g).

NMR (DMSO-d₆, δ): 0.90 (3H, d, J=6.8Hz), 0.97 (3H, d, J=6.6Hz), 1.13 (3H, d, J=5.0Hz), 1.43-6.10 (78H, m), 6.69-8.72 (18H, m)

ESI MASS (Negative): (m/z) 1418.4 (M⁻)

Example 26

To a suspension of the starting compound (26) (0.38 g) in a mixture of methanol (7.6 ml) and tetrahydrofuran (1.9 ml) were successively added triphenylphosphine (0.04 g),

tetrakis(triphenylphosphine)palladium(0) (0.088 g) and morpholine (0.14 ml) with stirring and the mixture was stirred at ambient temperature for 15 hours. To the reaction mixture was added ethylacetate (100 ml). The resulting precipitate was collected by filtration and dried in vacuo. The precipitate was dissolved in a mixture of water and 1N sodium hydroxide and the solution was subjected to column chromatography on ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (100 ml) eluting with 40% acetonitrile in water. The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (26) (0.25 g).

NMR (DMSO-d₆, δ): 0.90 (3H, d, J=6.7Hz), 0.98 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.7Hz), 1.42-5.23 (56H, m), 6.69-8.92 (17H, m)

ESI MASS (Negative): (m/z) 1334.4 (M⁺)

Elemental analysis Calcd. for C₆₁H₈₂N₁₂O₁₈S₂·8H₂O:

C 49.52, H 6.68, N 11.36

Found : C 49.25, H 6.41, N 11.20

Example 27

The suspension of a mixture of the starting compound (27) (100 mg), 1,3-dihydroxyacetate (13.5 mg) and acetic acid (0.13 ml) in a mixture of methanol (1.5 ml) and dimethylformamide (0.7 ml) was added sodium cyanoborohydride (9.4 mg) with stirring at ambient temperature, and the mixture was stirred at the same temperature overnight. To the reaction mixture was added ethylacetate (20 ml). The resulting precipitate was collected by filtration and dried in vacuo. The precipitate was dissolved in a mixture of water and 1N sodium hydroxide and the solution was subjected to column chromatography on ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (50 ml) eluting with 40% acetonitrile in water. The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was

lyophilized to give the object compound (27) (55 mg).

NMR (DMSO-d₆, δ): 0.90 (3H, d, J=6.8Hz), 0.98 (3H, d, J=6.7Hz), 1.11 (3H, d, J=5.5Hz), 1.43-5.24 (62H, m), 6.69-8.85 (17H, m)

ESI MASS (Negative): (m/z) 1408.3 (M⁻)

Example 28

To a solution of a mixture of the starting compound (28) (7.5 g), 1,3-dihydroxyacetone (1.19 g) and acetic acid (1.14 ml) in a mixture of methanol (120 ml) and dimethylformamide (55 ml) was added sodium cyanoborohydride (835 mg) with stirring at ambient temperature, and the mixture was stirred at the same temperature overnight. To a reaction mixture was poured into ethyl acetate (700 ml). The resulting precipitates were collected by filtration, washed with ethyl acetate (100 ml) and dried in vacuo. The precipitates were dissolved in a mixture of 30% aqueous acetonitrile (800 ml) and 1N sodium hydroxide (5 ml). The solution was subjected to column chromatography on ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (440 ml) eluting in turn with water and aqueous acetonitrile (30%-60%). The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (28) (5.22 g).

IR (KBr): 1632, 1535, 1518, 1443, 1269, 1082, 1047 cm⁻¹

NMR (DMSO-d₆+D₂O, δ): 0.82 (3H, d, J=6.83Hz), 0.97 (3H, d, J=6.81Hz), 1.02 (3H, d, J=6.18Hz), 1.24 (26H, S), 1.35-2.45 (14H, m), 2.75-3.40 (5H, m), 3.60-4.50 (15H, m), 4.70-4.90 (2H, m), 6.65-6.80 (2H, m), 7.01 (1H, S)

ESI MASS (Positive): (m/z) 1088.4 (M⁺+Na)

Example 29

To a solution of the starting compound (29) (4.0 g) in dimethylformamide (40 ml) were successively added diisopropylethylamine (1.45 ml) and 9-fluorenylmethyl

chloroformate (1.03 g), and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was poured into water (200 ml). The solution was purified by ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (200 ml) column chromatography, eluting in turn with a mixture of saturated aqueous sodium chloride (400 ml), saturated aqueous sodium hydrogen carbonate (50 ml) and water (400 ml), and aqueous acetonitrile (30-60%). The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give the object compound (29) (2.82 g).

IR (KBr): 1666, 1632, 1518, 1446, 1273, 1246, 1082, 1047
cm⁻¹

NMR (DMSO-d₆+D₂O, δ): 0.80-1.10 (9H, m), 1.23 (26H, s),
1.35-2.45 (12H, m), 2.60-3.40 (6H, m), 3.60-4.55 (18H,
m), 4.65-4.90 (2H, m), 6.65-6.85 (2H, m), 6.97 (1H, s),
7.30-7.50 (4H, m), 7.60-7.95 (4H, m)

ESI MASS (Negative): (m/z) 1423.7 (M⁻-Na)

Elemental analysis Calcd. for C₆₉H₉₉N₈O₂₂SNa·6H₂O
: C 53.27, H 7.19, N 7.20
Found: C 53.45, H 7.21, N 7.10

Example 30

To a solution of the object compound (30) (1.21 g) in dimethylformamide (15 ml) were successively added diisopropylethylamine (0.26 ml) and di-tert-butyl dicarbonate (285 mg), and the mixture was stirred at ambient temperature overnight. The reaction mixture was poured into a mixture of pH6.86 standard buffer solution (150 ml), saturated aqueous sodium chloride (50 ml) and saturated aqueous sodium hydrogen carbonate (20 ml). The mixture was purified by ODS (Daiso-gel, SP-120-40/60-ODS-B (Trade mark: prepared by Daiso Co. Ltd.)) (200 ml) column chromatography, eluting with aqueous acetonitrile (30-50%). The fractions containing the object compound were collected and evaporated under reduced pressure to remove acetonitrile. The residue was lyophilized to give

the object compound (30) (1.19 g).


IR (KBr) : 1662, 1632, 1535, 1518, 1444, 1367, 1272, 1250
cm⁻¹

NMR (DMSO-d₆+D₂O, δ): 0.85 (3H, d, J=6.76Hz), 0.96 (3H,
d, J=6.77Hz), 1.04 (3H, d, J=5.50Hz), 1.23 (26H, S),
1.37 (9H, S), 1.40-1.50 (2H, m), 1.55-2.50 (10H, m),
2.80-3.40 (6H, m), 3.50-4.45 (14H, m), 6.65-6.80 (2H,
m), 6.96 (1H, S)

ESI MASS (Negative): (m/z) 1301.6 (M⁺-Na)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A polypeptide compound of the following general formula
(I) :



wherein


- 20 R¹ is hydrogen or acyl group,
R² and R³ are independently hydrogen, lower alkyl which
may have one or more suitable substituent(s) or
acyl group,
R⁴ is hydrogen or hydroxy,
25 R⁵ is hydrogen, hydroxy or hydroxysulfonyloxy and,
R⁶ is hydroxy or acyloxy
or a salt thereof.

2. A compound of claim 1, wherein
- 30 R¹ is hydrogen or acyl group,
R² is hydrogen,
R³ is lower alkyl which has one or more hydroxy,
R⁴ is hydrogen or hydroxy,
R⁵ is hydroxysulfonyloxy and,
35 R⁶ is hydroxy.

3. A process for preparing a polypeptide compound (I) of claim 1, or a salt thereof, which comprises,


5

- i) reducing a compound (II) of the formula :




wherein R^1 , R^4 , R^5 and R^6 are defined in claim 1,
 R_a^2 is hydrogen, lower alkyl which may have one
 or more suitable substituent(s) or, acyl
 group, and
 R_a^3 is lower alkyl which may have one or more
 suitable substituent(s), or acyl group,
 or a salt thereof, or

iii) reducing a compound (Ic) of the formula :




wherein R^1 , R^2 , R^3 , R^4 and R^6 are defined in claim 1, and
 R_a^5 is hydroxysulfonyloxy,
 or a its reactive derivative at the sulfonic acid group,
 or a salt thereof, to hydrolysis reaction of the
 sulfonic acid group, to give a compound (Id) of the
 formula :



15

wherein R^1 , R^2 , R^3 , R^4 and R^5 are defined in claim 1, and
 R^5_b is hydroxy,
 or a salt thereof, or

iv) subjecting a compound (Ie) of the formula :



35

wherein R^1 , R^4 , R^5 and R^6 are defined in claim 1, and
 R^3_b is amino protective group,
 or a salt thereof, to elimination reaction of amino
 protective group, to give a compound (Ia) of the

[REDACTED]



10

20

25

25


30

35

Dated this 21st day of February, 2000
Fujisawa Pharmaceutical Co., Ltd.
By DAVIES COLLISON CAVE
Patent Attorneys for the Applicant

A B S T R A C T

This invention relates to new polypeptide compound represented by the following general formula (I) :



wherein

R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on b-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.